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Abstract
Lifestyle factors are responsible for a considerable portion of cancer incidence worldwide, but credible estimates from the 
World Health Organization and the International Agency for Research on Cancer (IARC) suggest that the fraction of cancers 
attributable to toxic environmental exposures is between 7% and 19%. To explore the hypothesis that low-dose exposures to 
mixtures of chemicals in the environment may be combining to contribute to environmental carcinogenesis, we reviewed 
11 hallmark phenotypes of cancer, multiple priority target sites for disruption in each area and prototypical chemical 
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disruptors for all targets, this included dose-response characterizations, evidence of low-dose effects and cross-hallmark 
effects for all targets and chemicals. In total, 85 examples of chemicals were reviewed for actions on key pathways/
mechanisms related to carcinogenesis. Only 15% (13/85) were found to have evidence of a dose-response threshold, whereas 
59% (50/85) exerted low-dose effects. No dose-response information was found for the remaining 26% (22/85). Our analysis 
suggests that the cumulative effects of individual (non-carcinogenic) chemicals acting on different pathways, and a variety 
of related systems, organs, tissues and cells could plausibly conspire to produce carcinogenic synergies. Additional basic 
research on carcinogenesis and research focused on low-dose effects of chemical mixtures needs to be rigorously pursued 
before the merits of this hypothesis can be further advanced. However, the structure of the World Health Organization 
International Programme on Chemical Safety ‘Mode of Action’ framework should be revisited as it has inherent weaknesses 
that are not fully aligned with our current understanding of cancer biology.
Introduction
Cancer is a burden on humanity and among the leading causes 
of morbidity and mortality worldwide, with ~14 million new 
cases and 8.2 million cancer-related deaths in 2012 (1). In gen-
eral, both genetic and environmental factors play a role in an 
individual’s cancer susceptibility (2,3), so there has been a long-
standing emphasis on avoidable ‘lifestyle’ factors (i.e. those 
that can be modified to reduce the incidence of the disease) and 
a parallel focus on exogenous chemical exposures (e.g. agricul-
tural, occupational and so on) (4). But advances in our under-
standing of the complexity of cancer biology have resulted in 
serious critiques of current risk assessment practices related 
to exogenous exposures (5) along with calls for an expanded 
focus on research that will allow us to evaluate the (potentially 
carcinogenic) effects of in-utero exposures and low-level expo-
sures to combinations of chemicals that occur throughout our 
lifetime (6,7).
The 2008–09 President’s Cancer Panel Annual Report in the 
USA (8) opined that the ‘true burden of environmentally induced 
cancer has been grossly underestimated’ (7), whereas Parkin 
et al. (9) estimated in a British study that the fraction of cancer 
that can now be attributed to both lifestyle and environmen-
tal factors is only 43% (i.e. the underlying cause of 57% of all 
cancers is still unexplained). However, an expanded focus on 
research that will allow us to evaluate the (potentially carcino-
genic) contribution of low-level exposures to combinations of 
chemicals that occur in utero and throughout our lifetime is not 
a trivial undertaking. 
First of all, the number of chemicals to which we are exposed 
is substantial, and many have not been adequately tested. 
Christiani (6) cited increased and persistently high incidence 
rates of various cancers and called on the National Institutes of 
Health to expand their investigation of environmental causes 
of cancer noting that ‘Massive gaps exist in toxicologic data, 
even in the case of widely used synthetic chemicals. Only about 
50% of chemicals classified by the Environmental Protection 
Agency (EPA) as “high production volume” have undergone 
even minimal testing for carcinogenicity’. But even though the 
incidence of cancer attributable to environmental exposures 
has not been definitively established (3,6), it remains an impor-
tant focus of our prevention efforts [with credible estimates 
from the World Health Organization [WHO] and the IARC sug-
gesting that the fraction of cancers attributable to toxic envi-
ronmental exposures is between 7% and 19%] (10,11).
The possibility that unanticipated low-dose effects (LDE) are 
also a factor in environmental carcinogenesis further compli-
cates matters. Vandenberg et al. (12) recently reviewed the accu-
mulating evidence that points to LDE that occur at levels that are 
well below those used for traditional toxicological studies. This 
review identified several hundred examples of non-monotonic 
dose-response relationships (i.e. examples where the relation-
ship between dose and effect is complex and the slope of the 
curve changes sign—from positive to negative or vice versa—
somewhere within the range of doses examined). Drawing on 
the known actions of natural hormones and selected environ-
mental chemicals examined in cell cultures, animals and epi-
demiology, the authors emphasized that when non-monotonic 
dose-response curves occur, the effects of low doses cannot be 
predicted by the effects observed at high doses. However, endo-
crine disruption research to this point has been aimed primarily 
at chemicals that disrupt developmental processes through a rel-
atively small subset of hormones (e.g. estrogen, androgen, thyroid 
and so on), and thus, many commonly encountered chemicals 
have not been tested at all for these effects (at environmentally 
relevant dose levels) and, to date, mechanisms that relate to car-
cinogenesis have typically not been the focus of these studies.
Generally for chemical risk assessments, toxicity stud-
ies are conducted with individual chemicals in animal mod-
els based on regulatory test guidelines [e.g. Organization for 
Economic Co-operation and Development (OECD) test guide-
lines (13)] with a key objective of providing a dose-response 
assessment that estimates a point of departure [traditionally 
the no-observed-adverse-effect level or the lowest-observed-
adverse-effect level (LOAEL)], which is then used to extrapo-
late the quantity of substance above which adverse effects can 
be expected in humans. The no-observed-adverse-effect level, 
combined with uncertainty factors (which acknowledge gaps 
in the available data), is then used to establish safety criteria 
Abbreviations 
AhR aryl hydrocarbon receptor 
BPA bisphenol A
EMT epithelial-mesenchymal transition
EPA environmental protection agency 
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for human exposure. However, in order to be able to detect 
adverse effects utilizing classical toxicological endpoints, dose 
selection has historically involved the use of high dose levels 
and appropriate dose level spacing to obtain the LOAEL or no-
observed-adverse-effect level thresholds. Techniques such as 
linear extrapolation or benchmark dose modeling (14) are then 
employed to predict safety margins for low-dose exposures. 
This approach to risk assessment depends on the use of appro-
priate and sensitive endpoints, and on valid assumptions for 
extrapolation estimates (e.g. dose-response linearity) and cal-
culations, and on the existence of thresholds of effects (15–17). 
So when the potential for non-linear dose-response relation-
ships is combined with the possibility of synergism between 
and amongst low doses of mixtures of individual chemicals in 
the environment, it appears plausible that chemicals that are 
not individually carcinogenic may be capable of producing car-
cinogenic synergies that would be missed using current risk 
assessment practices.
The complex nature of the biology of cancer adds another 
layer of complexity for risk assessment. In a landmark paper 
in 1979, Ames (18) noted that damage to DNA appeared to 
be a major cause of most cancers and suggested that natu-
ral chemicals in the human diet and the tens of thousands 
of man-made chemicals that had been introduced into the 
environment in the preceding decades be tested for their abil-
ity to damage DNA. In doing so, he sketched out the difficulty 
of dealing with complex chemical mixtures and he proposed 
the use of rapid mutagenicity assays to identify environ-
mental mutagens and carcinogens. The strategy was sound 
at the time, but it led to a scientific and regulatory emphasis 
on ‘mutagens as carcinogens’, whereas the issue of complex 
environmental mixtures, or carcinogens that are not muta-
gens, was never vigorously pursued. Instead, what followed 
was an international quest to find individual chemicals and 
a few well-defined mixtures (e.g. diesel exhaust) that could be 
shown to be ‘complete’ carcinogens (i.e. substances that could 
cause cancer on their own).
However, advances in cancer biology have revealed the 
limitations of this approach. Armitage and Doll first laid out 
a multistage theory of carcinogenesis in 1954 (19), and by 
1990, initiation and promotion were well established as dis-
crete steps in the evolution towards malignancy, along with 
the influence of ‘free radicals’, proto-oncogenes, oncogenes, 
epigenetic mechanisms and other synergistic or antagonistic 
factors (20). In 2000, Hanahan et al. (21) gave structure to this 
rapidly growing field of research with the proposal that ‘the 
vast catalog of cancer cell genotypes [could be organized into] 
a manifestation of six essential alterations in cell physiology 
that collectively dictate malignant growth’. They called these 
alterations the Hallmarks of Cancer, defined as ‘… acquired 
capabilities’ common to most cancers that ‘… incipient cancer 
cells … [must acquire to] enable them to become tumorigenic 
and ultimately malignant.’ The hallmarks delineated at the 
time were as follows:
•	 Self-sufficiency in growth signals (later renamed proliferative 
signaling)—cancer cells grow at a seemingly unlimited rate.
•	 Insensitivity to antigrowth signals (evading growth suppres-
sors)—cancer cells are not subject to antigrowth signals or 
withdrawal of normal growth signals.
•	 Evading apoptosis (resisting cell death)—cancer cells avoid the 
usual process whereby abnormal or redundant cells trigger 
internal self-destroying (as opposed to cell death) mecha-
nisms.
•	 Limitless replicative potential (enabling replicative immortal-
ity)—cancer cells do not senesce (or age) and die after a lim-
ited number of cell divisions.
•	 Sustained angiogenesis (inducing angiogenesis)—cancer cells 
elicit new blood vessels to sustain growth.
•	 Tissue invasion and metastasis (activating invasion and 
metastasis)—in situ or non-invasive cancers, e.g. ductal carci-
noma in situ in the breast or carcinoma in situ in colon polyps, 
grow into pre-existing spaces but invasive tumors must cre-
ate a space to expand into normal tissue.
From this perspective risk assessments based on limited ‘mode 
of action’ information, assumptions of linear dose-response 
relationships and a focus on individual chemicals (as complete 
carcinogens) appeared to be inadequate to estimate human can-
cer risks. So in 2005, a scientist at the United States EPA called 
for a shift in risk assessment practices that would move the field 
towards the development of biomarkers directly related to the 
pathways found within the Hallmarks of Cancer framework (22). 
The Hallmarks of Cancer framework was subsequently revis-
ited by Hanahan et  al. (21) and expanded to encompass addi-
tional areas suggested by subsequent cancer research (23). This 
expansion included the following:
•	 Two enabling characteristics:
•	 Genome instability and mutation, which allows changes in one 
cell to pass to daughter cells through mutation or epigenetic 
changes in the parent cell DNA.
•	 Tumor-promoting inflammation, which helps cancer cells grow 
via the same growth signals normal cells provide to each 
other during wound healing and embryonic growth; inflam-
mation further contributes to the survival of malignant cells, 
angiogenesis, metastasis and the subversion of adaptive 
immunity (24).
•	 Two ‘emerging’ hallmarks:
•	 Avoiding immune destruction whereby tumor cells avoid 
immune surveillance that would otherwise mark them for 
destruction.
•	 Dysregulated metabolism, one of the most recognizable fea-
tures of cancer; its exclusion from the original list of hall-
marks (21) probably represented a significant oversight, as it 
constitutes one of the earliest described hallmarks of cancer 
(25,26). It is needed to support the increased anabolic and cat-
abolic demands of rapid proliferation and is likely an enabler 
of cancer development and its other associated hallmarks.
Unfortunately, risk assessment practices that are currently used 
to assess the carcinogenic potential of chemicals have changed 
very little (despite the vast literature that now underpins the 
main tenants of the Hallmarks of Cancer framework). For exam-
ple, a chemical that disrupts DNA repair capacity might prove 
to be non-carcinogenic at any level of exposure (when tested on 
its own), but that very same chemical may have the potential to 
be an important contributor to carcinogenesis (e.g. in the pres-
ence of mutagens that cause DNA damage). Similarly, a chemical 
that has immuno-suppressive qualities may not be carcinogenic 
on its own, but if it acts to suppress the immune response, it 
may contribute to carcinogenesis (by dismantling an important 
layer of defense) in the presence of other disruptive chemicals. 
Considering the multistep nature of cancer and the acquired 
capabilities implied by each of these hallmarks, it is therefore 
a very small step to envision how a series of complementary 
exposures acting in concert might prove to be far more carci-
nogenic than predictions related to any single exposure might 
suggest (see Figure  1). Interacting contributors need not act 
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simultaneously or continuously, they might act sequentially or 
discontinuously. So a sustained focus on the carcinogenicity of 
individual chemicals may miss the sorts of synergies that might 
reasonably be anticipated to occur when combinations of disrup-
tive chemicals (i.e. those that can act in concert on the key mech-
anisms/pathways related to these hallmarks) are encountered.
To address the biological complexity issue associated with 
chronic diseases, the EPA and other agencies have begun to pursue 
risk assessment models that incorporate biological information. 
This is the basis of the Adverse Outcome Pathway concept, a con-
struct that is gaining momentum because it ties existing knowl-
edge of disease pathology (i.e. concerning the linkage between 
a direct molecular initiating event and an adverse outcome at a 
biological level of organization) to risk assessment (27,28). This 
line of thinking inspired a recent initiative by the EPA, where 
the agency tested a proposal for characterizing the carcinogenic 
potential of chemicals in humans, using in-vitro high-through-
put screening (HTS) assays. The selected HTS assays specifi-
cally matched key targets and pathways within the Hallmarks 
of Cancer framework. The authors tested 292 chemicals in 672 
assays and were successfully able to correlate the most disrup-
tive chemicals (i.e. those that were most active across the vari-
ous hallmarks) with known levels of carcinogenicity. Chemicals 
were classified as ‘possible’/‘probable’/‘likely’ carcinogens or des-
ignated as ‘not likely’ or with ‘evidence of non-carcinogenicity’ 
and then compared with in-vivo rodent carcinogenicity data in 
the Toxicity Reference Database to evaluate their predictions. The 
model proved to be a good predictive tool, but it was developed 
only as a means to help the EPA prioritize many untested indi-
vidual chemicals for their carcinogenic potential (i.e. in order to 
establish priorities for individual chemical testing (29)).
What is still needed, is an approach employing the Hallmarks 
of Cancer framework that can be used to identify priority 
mixtures (i.e. those with substantive carcinogenic potential). 
Without a way to anticipate the carcinogenicity of complex 
mixtures, an important gap in capability exists and it creates 
a significant weakness in current risk assessment practices. 
Countries around the globe have made a significant investment 
in the regulatory infrastructure and risk assessment practices 
that protect us from unwanted exposures to harmful chemicals 
and carcinogens, so we wanted to review the biology of cancer 
to map out the challenges associated with the development of 
an approach that would help us assess the carcinogenic poten-
tial of low-dose exposures to chemical mixtures in the envi-
ronment. Such an approach was seen as a reasonable step to 
provide impetus for progress in this area of research and ulti-
mately to inform risk assessment practices worldwide.
Materials and methods
In 2012, the non-profit organization ‘Getting to Know Cancer’ instigated 
an initiative called ‘The Halifax Project’ to develop such an approach using 
the ‘Hallmarks of Cancer’ framework as a starting point. The aim of the 
project was to produce a series of overarching reviews of the cancer hall-
marks that would collectively assess biologically disruptive chemicals (i.e. 
chemicals that are known to have the ability to act in an adverse manner 
on important cancer-related mechanisms, but not deemed to be carcino-
genic to humans) that might be acting in concert with other seemingly 
innocuous chemicals and contributing to various aspects of carcinogen-
esis (i.e. at levels of exposure that have been deemed to be safe via the 
traditional risk assessment process). The reviews were to be written by 12 
writing teams.
The writing teams were recruited by Getting to Know Cancer circu-
lating an email in July 2012 to a large number of cancer researchers, ask-
ing about their interest in the project. Respondents were asked to submit 
personal details through a dedicated webpage that provided additional 
project information. A  total of 703 scientists responded to the email, 
and from that group, 11 team leaders were selected to lead reviews of 
each hallmark (10 Hallmarks plus an 11th team to consider the tumor 
microenvironment as a whole) and one leader for the cross-validation 
Figure 1. Disruptive potential of environmental exposures to mixtures of chemicals. Note that some of the acquired hallmark phenotypes are known to be involved in 
many stages of disease development, but the precise sequencing of the acquisition of these hallmarks and the degree of involvement that each has in carcinogenesis 
are factors that have not yet been fully elucidated/defined. This depiction is therefore only intended to illustrate the ways in which exogenous actions might contribute 
to the enablement of these phenotypes. 
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team (see below). Writing group leaders were asked to form individual 
teams drawn from the pool of researchers who expressed interest in 
the project and from their own circles of collaborators. Leaders were 
encouraged to engage junior researchers as well. Team leaders received 
project participation guidelines and ongoing communication from the 
project leaders, L.Lowe and M.Gilbertson. Each team included: a lead 
author with a published expertise in the hallmark area; domain experts 
who assisted in the production of the descriptive review of the biology; 
environmental health specialists (e.g. specialists in toxicology, endo-
crine disruption, or other related disciplines) and support researchers.
Each writing team was charged to describe the hallmark, its systemic 
and cellular dysfunctions and its relationships to other hallmarks. A pri-
ority list of relevant (i.e. prototypical) target sites for disruption was to 
be developed by the team and a list of corresponding chemicals in the 
environment that have been shown to have the potential to act on those 
targets was requested, along with a discussion of related issues and future 
research needed (in the context of project goals).
Selection of target sites for disruption
A ‘target’ was broadly defined as a procarcinogenic disruption at the sys-
tem level (e.g. the hypothalamic–pituitary–gonadal axis), organ level, tis-
sue level or cellular level. It was assumed from the outset that a project 
intended to develop an approach for the assessment of the carcinogenic 
potential of low-dose exposures to chemical mixtures in the environment 
would encounter a practical upper limit to the number of potential targets 
that any given team could realistically review. Therefore, each team was 
asked to identify up to 10 relevant targets for their domain (bearing in 
mind that each target would also serve as a starting point for the identi-
fication of a disruptive environmental chemical that had already shown 
a demonstrated ability to act on that target). In theory, it was understood 
that this could lead to as many as 110 targets for the entire project, and 
as the teams were also asked to select one disruptive chemical for each 
target, a maximum of 110 chemicals. 
In this phase, teams were asked to focus on specific gene changes 
common to many cancers as identified by The Cancer Genome Project 
(30) in order to estimate how the function of specific genes might be 
altered, not by specific gene mutations, but rather either by direct 
action or by epigenetic changes that might lead to the same functional 
ends. Most of these pathways and processes are found within both 
the hallmarks of cancer and the genomic frameworks, so teams were 
asked to evaluate both models and consider non-mutagenic/epigenetic 
pathways of interference as well (given that epigenetic changes such as 
DNA methylation and histone acetylation are relevant for cancer and 
often inducible by chemicals and may be transmitted to daughter cells).
Selection of disruptive chemicals
Teams were then asked to identify ‘prototypical’ chemicals in the envi-
ronment that had demonstrated an ability to act on the selected targets. 
During workshops in Halifax, the teams settled on the following criteria 
to guide their choices:
•	 Chemicals should be ubiquitous in the environment because we 
wanted the broadest possible relevance for the general popula-
tion.
•	 Chemicals should selectively disrupt individual targets such as 
specific receptors, specific pathways or specific mechanisms. Hypo-
thetically speaking, a chemical could affect more than one pathway, 
receptor and so on; indeed, we expected that most chemicals would 
likely exert a multitude of actions. However, we used the term ‘selec-
tively disruptive’ to encourage teams to avoid choosing mutagens 
that are randomly destructive in their action (i.e. unpredictable and 
capable of producing varying types of damage across a wide range 
of pathways).
•	 Chemicals should not be ‘lifestyle’ related, such as those encountered 
from tobacco, poor diet choices (e.g. red meats, French fries, lack of 
fruit and vegetables and so on), alcohol consumption, obesity, infec-
tions (e.g. human papillomavirus) and so on.
•	 Chemicals should not be known as ‘carcinogenic to humans’ (i.e. not 
IARC Group 1, carcinogens).
The choice to focus on environmental pollutants in this project was 
intentionally restrictive. Countries around the globe have made sig-
nificant investments in regulatory infrastructure and risk assessment 
practices to protect us from unwanted exposures to harmful chemicals 
and carcinogens. Therefore, we focused on chemicals that are com-
monly encountered in the environment. Primarily, we wanted to gen-
erate insights that would be valuable for cancer researchers who are 
specifically interested in environmental chemical exposures to chemical 
mixtures and/or those who are focused on risk assessment practices in 
general.
Dose-response characterizations and LDE
Given that much of the evidence in the toxicological literature that docu-
ments the disruptive actions of various chemicals has been produced 
under a wide range of differing experimental circumstances, we wanted 
to assess the quality and relevance of data that were gathered for expo-
sures discussed in this review. Specifically, for each chemical selected 
and each mechanism identified, teams were additionally tasked to iden-
tify any dose-response characterization results and/or relevant low-dose 
research evidence that might exist. The term ‘low dose’ was defined using 
the European Food Safety Authority definition (i.e. responses that occur at 
doses well below the traditional lowest dose of 1 mg/kg that are used in 
toxicology tests) and the definition for ‘LDE’ was based on the EPA defini-
tion (31)—as follows:
Any biological changes occurring
(a) in the range of typical human exposures or
(b)  at doses lower than those typically used in standard testing proto-
cols, i.e. doses below those tested in traditional toxicology assess-
ments (32), or
(c)  at a dose below the lowest dose for a specific chemical that has 
been measured in the past, i.e. any dose below the lowest observed 
effect level (LOEL) or LOAEL (33)
(d)  occurring at a dose administered to an animal that produces blood 
concentrations of that chemical in the range of what has been 
measured in the general human population (i.e. not exposed oc-
cupationally, and often referred to as an environmentally relevant 
dose because it creates an internal dose relevant to concentrations 
of the chemical measured in humans) (34,35).
Each team was then asked to categorize each chemical by using one of 
five possible categories (to determine the relevance and relative strength 
of the underlying evidence for each of the chemicals being considered). 
The categories were as follows: (i) LDE (i.e. levels that are deemed relevant 
given the background levels of exposure that exist in the environment); 
(ii) linear dose-response with LDE; (iii) non-linear dose-response with LDE; 
(iv) threshold (i.e. this action on this mechanism/pathway does not occur 
at low-dose levels) and (v) unknown. Additional details of the descriptions 
for each of these categories are shown in Table 1.
Cross-hallmark relationships
In recognition of the network of signaling pathways involved and the 
degree of overlap/interconnection between the acquired capabilities 
described in each hallmark area, the project included a cross-validation 
step to create a more complete mapping of the actions that might be 
anticipated as the result of an action on the target sites identified or by 
the disruptive effects of the chemicals selected. Given the diversity of the 
targets involved in the 11 hallmark areas, it was anticipated that inhibit-
ing or stimulating a target relevant to one hallmark may have an impact 
on other targets that are relevant, especially if both are linked via signal-
ing pathways.
Accordingly, the cross-validation team conducted additional back-
ground literature review of submitted targets and chemicals from each 
writing team, searching for evidence to identify cross-hallmark activity. 
Each potential target-hallmark or approach-hallmark interaction was 
assessed to determine whether the inhibition or activation of each tar-
get and the corresponding biological activity of each chemical might 
reasonably be expected to have either a procarcinogenic or anticarcinogenic 
effect on key pathways/processes in the various hallmark areas.
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The cross-validation team also sought out controversial interactions 
(i.e. mixed indications of hallmark-like effects) and instances where no 
known relationship existed. It was our belief that target sites or chemicals 
that demonstrated a substantial number of ‘anticarcinogenic’ effects in 
other hallmark areas would be less suitable to serve as instigating con-
stituents in the design of carcinogenic mixtures (where procarcinogenic 
synergy was being sought).
It is important to note that the cross-validation team was not 
given any restrictions for literature selection for this effort, and con-
tributing authors were restricted neither to results from low-dose 
testing, nor to that of cancer-related research. This approach was 
taken because it was realized at the outset that this sort of breadth 
and homogeneity (of low-dose evidence) does not yet exist in the lit-
erature. As a result, the types and sources of data gathered in this 
effort varied considerably, resulting in an admixture of reviews and 
original studies. Moreover, many studies that were cited in this effort 
only considered a chemical’s ability to instigate or promote an action 
that mimics a hallmark phenotype in a manner directionally consist-
ent with changes that have been associated with cancer. So, although 
we have referred to these actions as procarcinogenic and anticarci-
nogenic, as these changes are frequently neither fixed nor specific 
for cancer, the specificity of these changes and implications for car-
cinogenesis cannot and should not be immediately inferred from this 
data set. Short-term toxicity and toxic responses—particularly in data 
from in-vitro HTS platforms—must be distinguished from truly ‘carci-
nogenic’ long-term changes. In other words, the tabularized results 
from this particular aspect of the project were only compiled to serve 
as a starting point for future research. Where cross-hallmark effects 
were reported (at any dose level and in any tissue type), we wanted 
samples of that evidence to share with researchers who might be try-
ing to anticipate the types of effects that might be encountered in 
future research on mixtures of chemicals (in a wide range of possible 
research contexts).
Results
The results are presented roughly sequenced in a manner that 
captures the acquired capabilities found in many/most cancers. 
The section begins with two enabling characteristics found in 
most cancers Genetic instability and Tumor-promoting inflam-
mation, followed by Sustained proliferative signaling and 
Insensitivity to antigrowth signals, the two related hallmarks 
that ensure that proliferation is unabated in immortalized cells. 
These sections are followed by Resistance to cell death and 
Replicative immortality, two critical layers of defense that are 
believed to be bypassed in all cancers and then by dysregulated 
metabolism. Sections on Angiogenesis and Tissue invasion and 
metastasis follow and speak to the progression of the disease, 
and finally, the Tumor microenvironment and Avoiding immune 
destruction sections offer summaries related to the very last 
lines of defense that are defeated in most cancers. Additionally, 
dose-response characterizations and evidence of LDE are then 
presented for all of these areas and the results from the cross-
validation activity are summarized and reviewed.
Genetic instability
The phenotypic variations underlying cancer result from interac-
tions among many different environmental and genetic factors, 
occurring over long time periods (199). One of the most important 
effects of these interactions is genome instability—loosely defined 
as an increased likelihood of the occurrence of potentially muta-
genic and carcinogenic changes in the genome. The term is used 
to describe both the presence of markers of genetic change (such 
as DNA damage and aneuploidy) and intrinsic factors that per-
mit or induce such change (such as specific gene polymorphisms, 
defective DNA repair or changes in epigenetic regulation).
DNA damage—which can be caused by exposure to external 
chemicals or radiation, or by endogenous agents such as reactive 
oxygen or faulty replication—is an event that can initiate the 
multistep process of carcinogenesis (200). Protection is afforded 
at different levels; removal of damaging agents before they 
reach the DNA, by antioxidant defenses and the phase I/phase 
II xenobiotic metabolizing enzymes; a second line of defense, 
DNA repair, operating on the damage that occurs despite the 
primary protection; and as a last resort, apoptosis (programmed 
cell death), disposing of heavily damaged cells.
A clear sign of genome instability is aneuploidy—a deviation 
from the normal number of chromosomes (201). Aneuploidy is 
a very common feature of human cancers. Another hallmark of 
cancer is loss of the normal mechanism of telomere shortening, 
which allows abnormal cells to escape senescence, by avoid-
ing the body’s ‘editing’ processes that normally eliminate aging 
cells with their accumulated genome aberrations (202,203).
The genes of most significance for cancer are the (proto)-
oncogenes which, if defective, or abnormally expressed, lead 
to uncontrolled cell proliferation; tumor suppressor genes, the 
normal products of which tend to switch off replication to allow 
repair, and promote cell death if damage is excessive; and genes 
such as those involved in DNA repair that can—if faulty—lead 
to a ‘mutator phenotype’. Mutated proto-oncogenes and tumor 
suppressor genes are found in most if not all cancers and 
play key roles in cancer etiology (204–207). Rare mutations in 
DNA repair genes greatly increase the risk of cancer (208,209). 
However, the evidence for links between common variants of 
repair genes and cancer is generally inconclusive (210).
The term ‘epigenetics’ refers to covalent modifications of the 
DNA (methylation of cytosine in ‘CpG islands’ within regula-
tory regions of genes) or of the histones. These modifications 
can control gene expression and the pattern of modifications 
is altered in many cancers (211,212). For instance, hypometh-
ylation of proto-oncogenes can lead to overexpression, which 
is undesirable. MicroRNAs (miRNAs) are responsible for specific 
down-regulation of gene expression at a post-transcriptional 
level, by preventing translation from messenger RNAs. miRNAs 
participate in DNA damage responses and some miRNAs are 
deregulated in many cancers (213–215).
Mutations in germ and stem cells are potentially more seri-
ous than those in other cells as they are passed to the cells’ 
progeny within the developing embryo or regenerating tissue 
(216,217). There is a presumed survival benefit when stem cells 
tend to show a particularly stringent maintenance of genome 
integrity through cell cycle regulation and enhanced responses 
to DNA damage (218).
The selected ‘chemical disruptors’ that induce genome 
instability include chemicals that not only directly damage DNA 
or cause mutations, but act indirectly, via pathways such as DNA 
damage signaling, DNA repair, epigenetic regulation or mito-
chondrial function. They include the following:
Metals such as lead, nickel, cobalt and mercury (common 
water pollutants) are known to disrupt DNA repair (181,219), 
whereas nickel also affects epigenetic histone modification 
(189,191) and lead causes defective telomere maintenance 
(184,220). Alloy particles, containing tungsten, nickel and cobalt, 
can be inhaled and disrupt redox signaling (193,221). Titanium 
dioxide nanoparticles are also common in many consumer prod-
ucts and foods and have been reported to disrupt mitochondrial 
function and increase oxidative stress, as well as inhibit DNA 
repair and disrupt mitosis (194,222,223).
Acrylamide occurs in many fried and baked food products, 
and (apart from the well-known DNA adduct formation) can 
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inactivate many critical proteins by binding sulfhydryl groups 
(186).
Bisphenol A  (BPA) is a plasticizer used for manufactur-
ing polycarbonate plastics and epoxy resins, and it can leach 
from plastics into food and water. It is implicated in disruption 
of DNA methylation, histone acetylation and disturbance of 
miRNA binding (192,224,225), redox signaling (226) and induc-
tion of micronuclei through spindle defects in mitosis (227).
The fungicide benomyl is metabolized to carbendazim; 
both are classified as possible human carcinogens at present. 
The route of exposure is most likely ingestion via residues in 
crops. Benomyl disrupts the microtubules involved in the func-
tion of the spindle apparatus during cell division, leading to 
production of micronuclei (Frame,S.R. et al., unpublished report, 
Schneider,P.W. et al., unpublished report, (228)).
Halobenzoquinones are disinfection by-products in chlo-
rinated drinking water (229). Quinones are electrophilic com-
pounds, known to react with proteins and DNA to form adducts. 
These electrophylic chemicals can interact with functional thiol 
groups via Michaelis–Menton type addition, causing modifica-
tion of enzymes involved in methylation and demethylation 
(188). This mechanism might be shared by other xenobiotics 
that increase reactive oxygen species (ROS).
Human exposure to nano-sized materials used in cosmetics, 
biomedical compounds, textiles, food, plastics and paints has 
increased not only in a conscious way but also passively by the 
leakage of nanomaterials from different objects. Nanoparticles 
can induce genome instability via mitochondrial-related apop-
tosis (230), decreased DNA repair (222,230,231), hypoacetyla-
tion of histones (232), disruption of DNA methylation (231), 
up-regulation of miRNA (233), reducing telomerase activity 
(220) and—more specifically for carbon nanotubes—interact-
ing with components of the mitotic spindle during cell division 
or interacting with proteins directly or indirectly involved in 
chromosome segregation (197,234). Nano-sized materials can 
also produce inflammation and alteration of the antioxidant 
defenses that can lead to genome instability.
Tumor-promoting inflammation
One of the earliest hypothesized causes of tumors subsequently 
supported experimentally was the irritation hypothesis pro-
posed by Virchow. Although it was recognized initially that injury 
alone was insufficient for carcinogenesis, it was also recognized 
that ‘irritation may have an accessory or predisposing influence 
in tumor formation, and that it may be enough finally to upset 
the balance of a group of cells which for some other reason were 
already hovering on the brink of abnormal growth’ (235). Indeed, 
it is now recognized that inflammatory responses, similar to 
those associated with wound healing or infection, support the 
development of invasive carcinomas by altering the microen-
vironment in favor of proliferation, cell survival, angiogenesis 
and tumor cell dissemination while also disrupting antitumor 
immune surveillance mechanisms. In other words, inflamma-
tion plays a critical role in tumorigenesis (23,24).
Inflammation is an immediate and necessary host defense 
mechanism in response to infection or tissue injury by noxious 
stimuli. In tumor-associated inflammation, both the epithelium 
and the immune cells express receptors that signal the activa-
tion and production of a wide array of biologically active proteins 
most analogous to an unhealed wound. The sustained or uncon-
trolled release of potent and reactive molecules such as prosta-
glandins, cytokines, ROS and chemokines from both the tumor 
cell and the microenvironment constituents lead to progressive 
genomic instability, alterations in the integrity and function of 
the microenvironment including alterations in the vasculature 
(e.g. vascular hyperpermeability, neovascularization and angio-
genesis), as well as alterations in local immune dynamics. The 
cellular and molecular mechanisms include a diverse array of 
immune- and tumor-cell-derived effector molecules such as the 
proinflammatory reactive oxygen and nitrogen species, a num-
ber or cytokines, chemokines as well as cyclooxygenase-2 and 
its product, prostaglandin E2.
In general, there is a paucity of experimentation, and when 
present, inconsistent findings for the role of environmental 
chemicals as proinflammatory molecules and more so for a pro-
inflammatory action as a co-factors in carcinogenesis. However, 
some recent studies provide a credible mechanistic basis, par-
ticularly early life exposures that might act by disrupting the 
immune cell balance toward inflammation, and that manifest in 
adulthood. One example is BPA, one of the most abundant and 
best studied environmental endocrine disruptors, and its con-
troversial role as an immune disruptor. Specifically, studies in 
male rats found that early life BPA exposure leads to the devel-
opment of prostate intraepithelial neoplasia (a prostate cancer 
precursor lesion) through a pathological process that includes 
BPA-dependent epigenetic reprogramming of genes involved in 
the development of lateral prostate inflammation in adulthood 
(236,237).
This work in prostate is complemented by a much more 
extensive study of BPA effects on immune cell components, 
particularly the T-cell compartment, demonstrating that BPA 
acts as an immune disruptor by promoting ‘immune’ cell pro-
liferation though the exact nature of the effect on specific cells 
of the immune system is poorly delineated. Most interesting is 
the work by Yan et  al. (122), who reported findings suggesting 
that the timing of BPA exposure during development (prenatally, 
early life or adult) alters the effect of BPA on regulatory T cells. 
BPA actions also map over to the effects on the immune sys-
tem including the promiscuity of BPA for a number of nuclear 
receptors relevant to immune cells such as the estrogen recep-
tor and the aryl hydrocarbon receptor (AhR). As well, bulky BPA 
analogs may act as antagonists of members of the peroxisome 
proliferator-activated receptor (PPAR) family, an important fam-
ily of nuclear receptors with potent anti-inflammatory function 
(238,239). Effects on the PPAR nuclear receptors may also explain 
inflammation-associated phenotypes observed with exposures 
to certain phthalates and nonylphenol (4-NP).
A second example is the reported immunotoxic effects of 
atrazine (6-chloro-N-ethyl-N-(1-methylethyl)-1,3,5-triazine-2,4-
diamine) (240), a chemical that is the most commonly detected 
triazine herbicide in USA soil and water. Atrazine is banned 
by the European Union and drinking water exposures are sup-
posed to be limited in the USA to <3 µg/l (although exposures 
exceed this limit regularly), but the use of this chemical is high 
and increasing in Asia and other countries. Thus, atrazine is an 
important pesticide to which humans are exposed. Atrazine 
exhibits weak mutagenicity and low oncogenic properties, but 
research by a number of authors is emerging that suggests that 
immune system disruption might be a concern (132,240,241).
Although the majority of work on atrazine has been focused 
on its endocrine disrupting properties, there is also evidence 
to support immunotoxicity including effects on T-lymphocytes 
composition with oral dosing (242,243), modulation of nitric 
oxide production (244) and potential generation of ROS (245,246). 
The local production of reactive nitrogen species and ROS 
by mast cells and macrophages are among the better stud-
ied immune modulatory molecules for which recent evidence 
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supports important roles both in the tumor microenvironment 
and in the tumor progression (247–249). Notably, these reactive 
species trigger oxidative/nitrosative modifications, which can 
initiate redox signaling that tightly modulates the inflammatory 
response in a manner that is highly relevant for carcinogenesis 
(250,251).
We also looked at polybrominated diphenyl ethers (PBDEs) 
and their effects on inflammatory cytokines. Peltier et al. (128) 
recently found that placental explants treated with a mix-
ture of the cogeners BDE-47, -99 and -100 and then exposed 
to Escherichia coli were ‘reprogrammed’ toward a proinflam-
matory response (increased IL-1β and tumor necrosis factor 
α) and away from the expected anti-inflammatory response 
(decreased IL-10) compared with untreated placenta. Although 
these studies are preliminary, chronic PBDE exposure may 
lower the threshold for bacteria to stimulate a proinflammatory 
response, which has potential relevance given the established 
link between bacteria and certain cancers (e.g. Helicobacter pylori 
and gastric cancer), where tumor development is dependent on 
inflammation.
Vinclozolin was also of particular interest as an environmen-
tal chemical because transient early life exposures in utero have 
been linked to both adult-onset disease and transgenerational 
disease that involves inflammation (134,135). For example, tran-
sient vinclozolin exposure in utero has been shown to promote 
inflammation in the prostate (prostatitis) of postpubertal rats 
coupled with a down-regulation of the androgen receptor and 
increase in nuclear factor-κB (NF-κB). The late or delayed effect 
of exposure is hypothesized to reflect a mechanism whereby 
vinclozolin exposure during a critical development window 
imprints an irreversible alteration in DNA methyltransferase 
activity, leading to reprogramming of the androgen receptor (AR) 
gene(s), which manifest as inflammation in early adult life with 
adverse effects on spermatid number.
Similarly, 4-NP has been shown to increase progenitor white 
adipose levels, body weight and overall body size in rodents 
exposed prenatally. Like vinclozolin, 4-NP effects on adipogen-
esis in the perinatal period confer transgenerational inheritance 
of the obesogenic effects observable in F2 offspring, consistent 
with genome reprogramming through an epigenetic process 
(252) and others have reported immune and inflammation-
related effects (137,138) making it relevant to carcinogenesis a 
deserving further investigation.
Sustained proliferative signaling
Sustained proliferative potential is an essential component of 
cancerous growth. Progressive conversion of normal cells into 
cancer cells requires a series of genetic alterations, where each 
alteration confers one or more types of growth advantage. One 
such alteration that affords the transformed cell a distinct 
growth advantage over its normal counterparts is the acquired 
capacity of the cancer cell to proliferate in a sustained manner, 
so as to crowd out and outnumber the normal cell population 
(23). One of the fundamental differences between a normal and 
a transformed cell is that normal cells halt proliferation when 
subjected to growth inhibitory signals or in the absence of 
growth stimulatory signals (253). But tumor cells act to sustain 
proliferative signaling in several different ways. They can acti-
vate specific genes to produce relevant growth factors, which in 
turn bind to signaling receptors giving rise to an autocrine loop 
(254). Growth factors produced by tumor cells can also stimulate 
the proliferation of stromal cells that in turn produce growth 
factors to sustain tumor cell proliferation (255). Sustained pro-
liferation can additionally be maintained at the receptor level 
by truncation of signaling receptor proteins whereby the ligand-
activated switch is missing (256). Alternatively, the number of 
high-affinity receptor proteins may be increased to levels that 
will sustain proliferative signaling in otherwise normal growth 
factor levels. Finally, sustained proliferative signaling may well 
be the result of perpetual activation of the intracellular sign-
aling chain independent of growth factors or receptors (e.g. 
mutated ras (257) or truncated src (258) are intermediaries of a 
normal proliferation signaling chain responsible for sustained 
proliferation).
We hypothesized that disruptive environmental chemicals 
acting in a procarcinogenic manner by inducing what is referred 
to as ‘sustained cell proliferation’ likely exerted their action by 
interfering with some basic control mechanisms (23,253). For 
instance, they could achieve this by positively regulating tar-
gets within and outside the cell known to promote cell prolif-
eration or negatively regulating targets within and outside the 
cell known to halt cell proliferation. In this way, such chemicals 
could confer proliferative advantage to a distinct cell population 
and contribute to that population’s capability to successfully 
breach innate anticancer defense mechanisms and to become 
progressively autonomous.
Specifically, we identified a total of 15 ubiquitous chemical 
disruptors capable of producing sustained cell proliferation. The 
majority of these chemicals interacted with multiple targets, 
and we have tabled this information in our review. In summary, 
we identified several commonly used insecticides and fungi-
cides capable of causing sustained proliferation. These included 
cyprodinil, etoxazole, imazalil, lactofen, maneb, methoxychlor 
(MXC), phosalone, prochloraz and pyridaben, all of which tar-
geted estrogen receptor α and frequently other steroid hormone 
receptors such as androgen receptor (102,259–275). Most of 
these chemicals also targeted growth factors and their recep-
tors (264,267) and induced cytokines and cytokine receptors 
(identified by ToxCast high throughput assay). Top disrupting 
chemical fungicides and insecticides were MXC and cyprodinil, 
which each interacted with a total of six individual targets that 
further included the AhR (100), B-lymphocyte markers (ToxCast 
2009 high-throughput assay, both chemicals), AP-1 proteins/
transcription/translation regulators, downstream signaling 
molecules and cell cycle regulators (276,277). Other strong per-
formers for sustained proliferation were BPA (activated all tar-
gets activated by the insecticides and fungicides above except 
growth factors and their receptors, B lymphocyte markers and 
PPAR, but included cell cycle regulators alongside AP-1 proteins/
transcription/translation regulators and downstream signaling) 
(272,276,278,279) (also identified in ToxCast high-throughput 
assay, 2009), polyfluorinated octinoid sulfate and polybromi-
nated diphenylethers (flame retardants) that either activated 
AhR (280,281) or up to five other targets that included steroid 
receptors, growth factors, cytokines and cell cycle regulators 
(109) (ToxCast high-throughput assay 2009). Three other con-
tenders were phthalates (plasticizers that acted via three tar-
gets that included AhR, steroid hormone receptors and PPAR) 
(282–285), trenbolone acetate (a synthetic anabolic steroid 
that unsurprisingly acted through steroid hormone receptors) 
(120,286–290) and finally, edible oil adulterants (food contami-
nants produced during food processing that acted via down-
stream signaling) (291,292).
We have shown estrogen and androgen receptors to be 
important targets in relation to sustained proliferative signaling 
(293), and note that environmental estrogens and androgens are 
frequently recognized as prototypical disruptor(s) of this hall-
mark. Although this is a small sample, there are a great number 
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of chemicals in the environment, both naturally occurring and 
man-made, are estrogenic, interact with estrogen receptor and 
produce estrogen metabolites (just as naturally derived ovarian 
estrogen does during metabolic breakdown). Catechol estrogens 
(hydroxyl derivatives of estrogens), which are formed during 
estradiol metabolism, are also potentially important mediators 
of endogenous estradiol levels, and therefore of sustained pro-
liferative signaling and oncogenesis (294).
Insensitivity to antigrowth signals
Cell cycle arrest is important for maintaining genomic integrity 
and for preventing genetic errors from being propagated. The 
normal cell cycle contains multiple checkpoints to safeguard 
against DNA-damaging agents. Specific proteins at these check-
points are activated in response to harmful stimuli, ensuring 
that cellular proliferation, growth and/or division of cells with 
damaged DNA are blocked.
There are multiple key mediators of growth inhibition that 
may become compromised during carcinogenesis. Some, such 
as p53, RB1, and checkpoint kinases cause cells to arrest at the 
G1–S phase transition when they are activated by DNA damage. 
Mutations in the p53 gene occur in ~50% of all cancers, although 
certain tumor types, such as lung and colon, show a higher than 
average incidence (295). Similarly, pRb hyperphosphorylation 
(296), direct mutations (297), loss of heterozygosity (298) and dis-
ruption of the INK4–pRb pathway (INK4–CDK4/6–pRb–E2Fs) (299) 
are common events in the development of most types of can-
cer. Cancer cells may also evade the growth inhibitory signals 
of transforming growth factor-β (TGF-β) (300) and modulate the 
action of downstream effectors as well as crosstalk with other 
pathways.
Cells also receive growth inhibitory signals through intercel-
lular communication via gap junctions. Gap junctions disperse 
and dilute growth-inhibiting signals, thereby suppressing cell 
proliferation. In contrast, loss of gap junctions increases intra-
cellular signaling, leading to enhanced proliferation and tumor 
formation. The molecular components of gap junctions are the 
connexin proteins (301). Connexins are recognized as tumor sup-
pressors and have been documented to reduce tumor cell growth. 
Numerous environmental stimuli have been reported to directly 
affect gap junction intercellular communication. Adherens junc-
tion machinery mediates contact inhibition of growth, and loss 
of contact inhibition is a mediator of tumor cell growth.
Chemicals that may contribute to insensitivity to antigrowth 
signals through multiple targets of this hallmark are BPA, a 
common constituent of everyday plastics, and pesticides such 
as DDT, folpet and atrazine. BPA promotes proliferation by dis-
rupting the growth inhibitory signals of p53 and gap junction 
communication (171,302). DDT has also been shown to enhance 
proliferation by increasing the expression of Ccnd1 (cyclin D1)/
E2f, inducing phosphorylation of pRb, increasing the expression 
of p53-degrading protein Mdm2 (a negative regulator of p53) 
(162) and disrupting gap-junctional intercellular communica-
tion (163,164). Folpet down-regulates the functions of p53 and 
ATM/ATR checkpoint kinases (167) and promotes proliferation, 
whereas atrazine shows genotoxic effects at subacute dose on 
Wistar rats. Genotoxicity was also associated with increased 
transcription of connexin accompanied with increased oxida-
tive stress (303). 
Resistance to cell death
Cell death is an actively controlled and genetically regulated 
program of cell suicide that is essential for maintaining tis-
sue homeostasis and for eliminating cells in the body that are 
irreparably damaged. Cell death programs include: apoptosis, 
necrosis, autophagy senescence and mitotic catastrophe (21). 
Defects in these pathways are associated with initiation and 
progression of tumorigenesis. Normally, cells accumulate from 
an imbalance of cell proliferation and cell death, permissive cell 
survival amidst antigrowth signals such as hypoxia and con-
tact inhibition, resistance to the killing mechanisms of immune 
cell attack and anoikis resistance (304). Increased resistance to 
apoptotic cell death involves inhibition of both intrinsic and 
extrinsic apoptotic pathways.
The link between malignancy and apoptosis is exemplified 
by the ability of oncogenes, such as MYC and RAS, and tumor 
suppressor genes, such as TP53 and RB, to engage both apop-
tosis and the aberrant alterations of apoptosis regulatory pro-
teins such as BCL-2 and c-FLIP in various solid tumors (305). This 
variety of signals driving tumor evolution provides the selective 
pressure to alter apoptotic programs during tumor development. 
Some chemical carcinogens and sources of radiation cause DNA 
damage and increase genetic and/or epigenetic alterations of 
oncogenes and tumor suppressor genes leading to loss of cel-
lular homeostasis (306). Other signals include growth/survival 
factor depletion, hypoxia, oxidative stress, DNA damage, cell 
cycle checkpoint defects, telomere malfunction and oncogenic 
mutations, and exposure to chemotherapeutic agents and heavy 
metals (307,308).
Cancer cells resist apoptotic cell death by up-regulation of 
antiapoptotic molecules and the down-regulation, inactivation 
or alteration of pro-apoptotic molecules. Activation of p53 usu-
ally induces expression of pro-apoptotic proteins (Noxa and 
PUMA) and facilitates apoptotic cell death (309). Antiapoptotic 
Bcl-2 family proteins suppress pro-apoptotic Bax/Bak [which 
would otherwise inhibit mitochondrial outer membrane perme-
abilization]. Mitochondrial outer membrane permeabilization 
releases cytochrome c and triggers apoptosis through an intrin-
sic pathway (310). Thus, regulation of apoptosis can be achieved 
by inhibiting the antiapoptotic Bcl-2 family proteins and Bcl-XL 
proteins as this restores a cell’s ability to undergo apoptosis. In 
the process, mitochondrial outer membrane permeabilization, 
mitochondrial proteins (Smac/DIABLO and Omi/HtrA2), which 
inhibit the X-linked inhibitor of the apoptosis protein, are leaked 
to trigger caspase activity in apoptosis (311,312). 
Normal cellular metabolism is important for the sur-
vival of cells, whereas dysregulated metabolism in cells (see 
Dysregulated metabolism) can induce either apoptosis or resist-
ance to apoptotic stimuli (313). In the liver, nearly every enzyme 
in glycolysis, in the tricarboxylic acid cycle, in the urea cycle, in 
gluconeogenesis and in fatty acid and glycogen metabolism is 
found to be acetylated, and this N-α-acetylation confers sensi-
tivity to apoptotic stimuli (314). The antiapoptotic protein, Bcl-xL 
reduces the efflux of acetyl-CoA from the mitochondria to the 
cytosol in the form of citrate and decreases N-α-acetylation of 
apoptotic proteins, which enables cells less sensitive toward 
apoptotic stimuli to mediate cell proliferation, growth and sur-
vival. Thus, N-α-acetylation might be a major factor in overcom-
ing apoptotic resistance in cancer cells (315,316).
Death receptor ligands such as TRAIL—which is bound to 
DR4/DR5—induce receptor oligomerization and recruitment of 
FADD and caspase-8 to form death-inducing signaling com-
plex, which leads to subsequent cell death via apoptosis. Thus, 
expression of death receptors and their decoy receptors (Dcr1/2) 
mediates apoptosis in tumor cells (317). When normal cells lose 
contact with their extracellular matrix or neighboring cells, they 
undergo an apoptotic cell death pathway known as ‘anoikis’ 
(304). During the metastatic process, cancerous cells acquire 
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anoikis resistance and dissociate from primary sites, travel 
through the vascular system and proliferate in distant target 
organs.
A blockage of gap junction intracellular communication 
(GJIC) between normal and preneoplastic cells also creates an 
intra-tissue microenvironment in which tumor-initiated prene-
oplastic cells are isolated from growth controlling factors of nor-
mal surrounding cells resulting in clonal expansion (318). Gap 
junction channels and Cxs control cell apoptosis by facilitating 
the influx and flux of apoptotic signals between adjacent cells 
and hemi-channels between the intracellular and extracellular 
environments, and Cx proteins in conjunction with their intra-
cytoplasmic localization, may act as signaling effectors that are 
able to activate the canonical mitochondrial apoptotic pathway 
(319).
Several anthropogenic chemicals can affect resistance to cell 
death. For example, BPA has been shown to strikingly impair 
TP53 activity and its downstream targets, cell cycle regulators, 
p21WAF1 and RB, or pro-apoptotic BAX, thereby enhancing the 
threshold for apoptosis (172).
Chlorothalonil, a broad-spectrum fungicide that is used on 
vegetables, fruit trees and agricultural crops, is considered to be 
non-genotoxic but classified as ‘likely’ to be a human carcino-
gen by all routes of exposure (29). In a eukaryotic system, chlo-
rothalonil reacted with proteins and decreased cell viability by 
formation of substituted chlorothalonil-reduced glutathione 
derivatives and inhibition of specific nicotinamide adenine dinu-
cleotide thiol-dependent glycolytic and respiratory enzymes (320). 
Caspases (cysteine-dependent proteases) and transglutaminase 
are some of the thiol-dependent enzymes involved in apoptosis, 
so inhibition of these thiol-dependent enzymes in tumor-initiated 
cells may disrupt apoptotic cell death and aid in tumor survival.
Dibutyl phthalate and diethylhexyl phthalate (DEHP) are 
diesters of phthalic acid and commonly referred to as phtha-
lates. In general, mimic the function or activity of the endoge-
nous estrogen 17β-estradiol (E2) and bind to estrogen receptors. 
Interestingly, phthalates can mimic estrogen in the inhibition 
of TAM-induced apoptosis in human breast cancer cell lines by 
increasing intracellular Bcl-2/Bax ratio in breast cancer (321).
Lindane, an organochlorine pesticide, bioaccumulates in 
wildlife and humans. Exposure to lindane induces tumor for-
mation in the mouse 42GPA9 Sertoli cell line by disrupting the 
autophagic pathway and sustained activation of the mitogen-
activated protein kinase (MAPK)/extracellular signal-regulated 
kinase (ERK) pathway (322).
MXC (1,1,1-trichloro-2,2-bis(4-methoxyphenyl)ethane) is a 
DDT derivative that was developed after the ban of DDT and 
it exhibits antiandrogenic and estrogenic activity. MXC stimu-
lates proliferation and human breast cancer cell growth by the 
up-regulation of genes that involve cell cycle (cyclin D1), and the 
down-regulation of genes p21 and Bax affecting G1/S transition 
and apoptosis, respectively, through ERα signaling (323).
Replicative immortality
Cellular senescence is a state of irreversible arrest of cellular 
proliferation characterized by changes in transcription, chro-
matin conformation, cytoplasmic and nuclear morphology, 
DNA damage signaling and a strong increase in the secretion of 
proinflammatory cytokines (324) Senescence is the first line of 
defense against potentially transformed cells (325). Progression 
to malignancy correlates with a bypass of cellular senescence. 
Thus, senescence inhibits the activation of the tumorigenic 
process (325). Senescence has been observed in vitro and in vivo 
in response to various stimuli, including telomere shortening 
(replicative senescence), oncogenic stress, oxidative stress and 
chemotherapeutic agents (326).
Cellular senescence exhibits several layers of redundant 
regulatory pathways. These pathways converge to arrest the cell 
cycle through the inhibition of CDKs. The best-known effector 
pathways are the p16INK4a/pRB, the p19ARF/p53/p21CIP1 and 
the PI3K/mammalian target of rapamycin (mTOR)/FOXO path-
ways (327–330), which show a high degree of interconnection. 
Additionally, the pRb and the mTOR pathways are two routes 
that have been proposed to be responsible for permanent arrest 
of the cell cycle (331). More pathways and genes are being dis-
covered, increasing the complexity of our knowledge of this 
physiological process (329). Most, if not all of these genes have 
been related to human tumorigenesis.
Despite the relevance of senescence as a gatekeeper in the 
process of tumorigenesis, there is not a large body of infor-
mation exploring the effect of chemicals on this safeguard. 
Little research has been undertaken on chemicals that alter 
gene expression regulating senescence and few genes have 
been identified (e.g. telomerase, p53, pRb, INK4a) (83,332,333). 
Traditional protocols for the assessment of the carcinogenic 
risk rely on the detection of tumors induced by agents that 
alter many different pathways at the same time (includ-
ing senescence). These agents are mainly unspecific muta-
gens or epigenetic modifiers. The effect of some compounds 
is being explored including nickel-derived compounds (e.g. 
nickel chloride), diethylstilbestrol, reserpine or phenobarbital 
(83,334–337).
There may be environmental chemicals that are not muta-
gens or epigenetic modifiers, but that target specific proteins on 
the senescence pathways and may affect the initiation of tumo-
rigenesis by other compounds allowing senescence bypass. The 
contribution of these compounds to the carcinogenesis process 
is largely unknown. A  few compounds bypass senescence in 
this specific manner—acetaminophen, cotinine, nitric oxide, 
Na-selenite and lead. Other chemicals known to alter senes-
cence only are mostly unknown (86,88–91,338–341).
Senescence has strong fail-safe mechanisms, and experi-
mental attempts to bypass senescence are usually recognized 
as unwanted signals and trigger a senescence response anyway. 
However, these conclusions are based on the interpretations of 
experimental designs in which acute molecular or cellular alter-
ations are produced. There are few experiments regarding the 
effects of chronic, low-dose alterations and even fewer studies 
that consider the different cellular and molecular contexts that 
can arise over the course of a lifetime.
Dysregulated metabolism
The highly glycolytic cancer phenotype described by Warburg 
et al. (25) in the early 20th century determined much of the initial 
direction in cancer research (26). Other characteristic metabolic 
abnormalities have also been described (25,26,342,343) and have 
recently garnered increased attention (344–348). These changes 
are neither fixed nor specific for cancer (349–351), but the uni-
versality of metabolic dysregulation suggests major roles in can-
cer genesis, maintenance and progression. Precise definitions of 
what constitutes cancer metabolism, and when such changes 
first occur during the course of cancer development, are lacking. 
From a teleological perspective, alterations in both intermediary 
metabolism and its control are not surprising insofar as highly 
proliferative cancer cells exhibit increased energy demands 
and expanded requirements for macromolecular precursors to 
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support nucleic acid and protein biosynthesis, as well as mem-
brane biogenesis, for increased biomass. Metabolic reprogram-
ming ostensibly equips cancer cells to cope with these demands, 
as well as accompanying cellular stresses. Although much of 
the attention on cancer metabolism has focused on enhanced 
glucose utilization via glycolytic and pentose phosphate path-
ways, cancer cells are also capable of the oxidative utilization of 
carbohydrates, lipids and peptides, and the metabolism of these 
individual substrate classes remain intimately intertwined as in 
normal cells (26,345,352).
Major control of glycolysis is traditionally ascribed to glu-
cose transport, hexokinase, phosphofructokinase and pyru-
vate kinase (352). Glyceraldehyde-3-phosphate dehydrogenase 
also normally couples glycolytic flux to mitochondrial metabo-
lism in the presence of oxygen and to lactate generation in its 
absence, but this relationship is fundamentally altered in can-
cer (26,345,353,354). Given the central importance of the pen-
tose phosphate pathway to anabolic metabolism and redox 
homeostasis, glucose-6-phosphate dehydrogenase and its redox 
coupling partners represent similarly attractive carcinogenic 
targets (355). In addition, the enzymes of the tricarboxylic acid 
cycle, such as fumarate hydratase, succinate dehydrogenase 
and isocitrate dehydrogenase, play crucial roles in oxidative 
energy metabolism and the interconversion of metabolic inter-
mediates, making them appealing candidates for study as well 
(356,357).
The central importance of the mitochondrial electron trans-
port chain to oxidative energy metabolism and its established 
role in toxic responses and dysregulated mitochondrial func-
tion in cancer makes its assembly and function attractive topics 
for study (358–360). Despite well-established roles for lipid and 
amino acid metabolism in cancer development and progression, 
they have historically received less attention than carbohydrate 
metabolism (26). Lipogenic, lipolytic and lipophagic pheno-
types are now widely recognized (344,361–363), so targets such 
as acetyl-CoA carboxylase, fatty acid synthase, cellular lipases 
and lipid transporters represent additional attractive targets 
for study. Amino acid metabolism—particularly glutamine and 
serine metabolism—also has well-established roles in cancer 
(364–366), providing additional potential targets for study that 
include 3-phosphoglycerate dehydrogenase (346,365,367,368) 
and cellular transaminase coupling mechanisms. Study of 
both lipid and protein metabolism must accommodate the fact 
that cancer cells exhibit substrate preferences, including well-
described endogenous lipid- and protein-sparing effects of 
exogenous glucose availability in cancer cells.
The metabolic capacity of both normal cells and cancer cells 
generally exceed their catabolic and anabolic requirements 
(364,369,370), and only a fraction of the available potential energy is 
ultimately required for cell survival (371,372). Moreover, very small 
changes in metabolic flux can have profound phenotypic conse-
quences, and metabolic control analysis has suggested that the 
importance of increased cancer-associated glycolytic and glutami-
nolytic fluxes may lie not in their magnitudes, but in the mainte-
nance and control of smaller branched pathway fluxes (364). For 
these reasons, rigorous functional validation is needed for all can-
cer-associated changes in gene expression or metabolite accumu-
lation. Well-described moonlighting functions for many metabolic 
enzymes (373–375), including the novel antiapoptotic roles of mito-
chondrial hexokinases (376), cannot be simply extrapolated from 
our knowledge of classical roles in cellular metabolism.
These enzymes and their pathways constitute broad cat-
egories of potential targets for disruption that could serve to 
enable the observed metabolic phenotypes of cancer cells (377). 
Although metabolic control is broadly distributed over all indi-
vidual steps for a given pathway (352,378), the most obvious 
targets for conceptual and experimental scrutiny involve major 
rate-controlling elements of pathways capable of supporting the 
anabolic and catabolic needs of rapidly proliferating cancer cells.
Numerous studies have demonstrated cancer-associated 
changes in metabolism or related gene expression (26). We 
looked at acrolein, copper, cypermethrin, diazinon, hexythi-
azox, iron, malathion and rotenone as chemicals that had been 
reported to show relevant disruptive potential (51,379–383); 
however, the toxicological data that are available for many 
suspected or known environmental disruptors, generally lacks 
mechanistic information regarding their potential roles as 
determinants of the observed metabolic hallmarks of cancer. 
Even prior metabolic screening platforms, including tetrazolium 
reduction assays, have limited specificity and can be profoundly 
influenced by experimental screening conditions. Unfortunately, 
standardized chemical screening has typically not been con-
ducted under controlled or limiting substrate conditions that 
would directly inform our understanding of the functional rel-
evance of observed changes. None have established unambigu-
ous causal relationships between specific chemical exposures 
and the parallel or sequential development of dysregulated 
metabolism of cancer in the same model, and most observed 
changes in gene expression with potential relevance to cancer 
metabolism have not been accompanied by validating func-
tional studies.
Angiogenesis
Angiogenesis, the process of formation of new blood vessels 
from existing blood vessels, is a critical process for normal organ 
function, tissue growth and regeneration (e.g. wound healing, 
female menstruation, ovulation and pregnancy) as well as for 
pathological conditions (e.g. cancer and numerous non-cancer-
ous diseases, such as age-related macular degeneration, dia-
betic retinopathy, rheumatoid arthritis, endometriosis, diabetes 
and psoriasis) (384,385).
Tumor angiogenesis is an early critical event for tumor 
development: A tumor cannot grow beyond 1 mm3 (by estimate) 
without angiogenesis (386). Tumor growth, invasion and metas-
tasis depend on blood vessels and neovascular development 
to provide nutrients, oxygen and removal of metabolic waste 
as tumors grow in primary sites, invade adjacent tissues and 
metastasize to distant organs (387,388). Inhibition or eradication 
of tumor angiogenesis by antiangiogenic inhibitors (389,390) or 
by antineovascular agents (such as vascular-disrupting agents 
(391–393) and fVII/IgG Fc (394), the latter also called ICON (395–
397)) can treat pathological angiogenesis-dependent diseases, 
including cancer and many non-cancerous diseases.
Under physiological conditions, angiogenesis is well bal-
anced and controlled by endogenous proangiogenic factors 
and antiangiogenic factors. Factors produced by cancer cells 
can shift the balance to favor tumor angiogenesis. Such factors 
include vascular endothelial growth factor (VEGF) and tissue 
factor (TF). VEGF, one of the most potent proangiogenic factors 
produced by cancer stem cells and cancer cells, binds to vascular 
endothelial cells via its receptor VEGFR, initiating VEGF/VEGFR 
intracellular signal transduction pathways and activating many 
gene transcriptions and translations toward angiogenesis. TF 
is a transmembrane receptor (398) not expressed on quiescent 
endothelial cells (399,400). Upon stimulation of VEGF, TF is selec-
tively expressed by angiogenic endothelial cells, the inner layer 
of the tumor neovasculature. Thus, TF is a specific biomarker 
for tumor angiogenesis (408–410). Both of the membrane-bound 
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receptors VEGFR and TF can mediate separate intracellular sign-
aling pathways that contribute to tumor angiogenesis.
Environmental exposures can promote tumor development, 
but the role of chemicals in tumor angiogenesis, particularly the 
role of low-dose non-carcinogens, is largely unknown. Some food-
use pesticides that are non-genotoxic act as tumor promoters, 
and other chemicals affect various hallmarks such as apoptosis, 
proliferative signaling, evading growth suppression, enabling 
replicative immortality, metastasis, avoiding immune destruc-
tion, tumor-promoting inflammation and deregulating cellular 
energetics—in addition to tumor angiogenesis.
Chemical disruptors that may promote tumor angiogenesis 
included diniconazole, 2,2-bis-(p-hydroxyphenyl)-1,1,1-trichlo-
roethane (HPTE), methylene bis(thiocyanate), perfluorooctane 
sulfonate (PFOS), Ziram, biphenyl, chlorothalonil, tributyltin 
chloride and bisphenol AF. Diniconazole (pesticide), for exam-
ple, targets certain angiogenic molecules (CXCL9, CXCL10, 
MMP1, uPAR, VCAM1 and THBD) in vitro (29). MXC (the parent 
compound to HPTE) induces histological expression of angio-
genic factors such as VEGF, VEGFR2 and ANG1 in rat pituitary 
and uterus (39), and exposure to PFOS induces actin filament 
remodeling, endothelial permeability changes and ROS produc-
tion in human microvascular endothelial cells (41). Ziram can 
induce angiogenesis through activation of MAPK and decreases 
cytolytic protein levels in human natural killer (NK) cells 
(404,405).
Tissue invasion and metastasis
Tissue invasion and metastasis are also key processes of tumor 
progression. In normal cells, E-cadherin holds the epithelial 
cells together as a society of cells that are well differentiated 
and otherwise quiescent (406). Carcinomas constitute almost 
90% of cancers and upon oncogenic transformation, the process 
of tissue invasion and metastasis begins with the down-regu-
lation of E-cadherin. Concomitant with this down-regulation of 
E-cadherin is the conversion of epithelial to mesenchymal cells 
(EMT) (407). The transcription factors that control EMT, such as 
snail, slug, Twist and Zeb1/2, are some of the best-character-
ized signaling molecules in biology (408,409). During the pro-
cess of EMT, a number of inflammatory cells are attracted to 
the growing tumor mass (410). Upon attaining mesenchymal 
characteristics, tumor cells are able to move out of their natu-
ral environment, aided by cross talk between them and stromal 
cells, resulting in the secretion of matrix degrading enzymes 
such as matrix metalloproteinases (411). This process is accel-
erated by chronic inflammation mediated by NF-κB (410). Other 
invasion mediating molecules include hepatocyte growth fac-
tor, secreted mainly by tumor-associated fibroblasts to signal 
metastatic cells to move upon their interactions with their cell 
surface receptor cMet (412).
Attracted by chemokines, metastatic cells move to the near-
est blood vessel or lymphatic vessel, where they complete the 
process of intravasation, entering the capillaries and are then 
transported to the capillary bed in their colonized site or new 
environment (413). In this new location, tumor cells undergo 
extravasation where they come out of the capillaries or lym-
phatic vessels, most likely again following the cues emanat-
ing from the chemokines in their new microenvironments. To 
survive in their new home, they may have to revert back and 
assume the cuboidal morphology of epithelial cells-undergo-
ing the reversal of EMT otherwise known as mesenchymal to 
epithelial transition (414). At this point, they may remain dor-
mant for a very long time until conditions for their division and 
growth become favorable.
Mounting evidence supports the involvement of exosomes 
(nano-vesicles secreted by tumor or cancer-associated fibro-
blasts) in adhesion and motility of metastatic cells. The secretion 
of exosomes is accelerated by increases in intracellular cal-
cium ions, and low-dose environmental mixtures that increase 
intracellular calcium may promote the secretion of exosomes 
and the subsequent invasion and metastasis processes of the 
tumor cells.
Environmental chemicals, such as tetrabromobisphenol 
A and its metabolites, BPA and tetrabromobisphenol A dimethyl 
ether, which mediate the activation of EMT enzymes or drive 
their synthesis, may also contribute to the process of tissue 
invasion (415). Low-dose exposure to hexavalent chromium may 
accelerate the EMT transition (416). Other contributing factors 
may also be low-dose environmental contaminants, such as for-
maldehyde, or bacteria, e.g. H. pylori, that drive the transcription 
of NF-κB and exacerbate the process (417,418).
Tumor microenvironment
The tumor microenvironment is a complex mix of cells in addi-
tion to tumor cells themselves; it is constructed of a complex 
balance of blood vessels that feed the tumor, the extracellu-
lar matrix that provides structural and biochemical support, 
signaling molecules that send messages, soluble factors such 
as cytokines and many other cell types. Tumors can influence 
the microenvironment and vice versa. The micro-environmental 
reaction to early tumor cells begins with the recruitment and 
activation of multipotent stromal cells/mesenchymal stem cells, 
fibroblasts, endothelial cell precursors, antigen-presenting cells 
such as dendritic cells (DCs) and other white blood cells. All of 
these tumor stromal cells secrete a variety of growth factors and 
chemokines that, together with the tumor cells and secreted 
factors, culminate in the generation of the tumor microenviron-
ment (419–422).
The tumor microenvironment is important because any cell 
within this process has the potential to be affected by carcino-
gens, either alone or in mixtures, or by the inflammation that 
results from the carcinogenic insult (423). Although often asso-
ciated with infection, chronic inflammation can be caused by 
exposure to carcinogens such as irradiation or environmental 
chemicals. Carcinogenesis can also be fostered via effects on the 
tissue context surrounding preneoplastic lesions. For example, 
transplantation experiments of preneoplastic cells have clearly 
documented that a growth-constrained tissue microenviron-
ment can promote the growth and progression of preneoplastic 
cell populations (424).
Several compounds appear to influence the complex het-
erogeneity that forms the support network for cancer growth. 
The exposure to nickel chloride has been associated with the 
generation of ROS and inflammation (425). ROS are impor-
tant because they can stimulate the induction of angiogenesis 
growth factors, such as VEGF, and can promote cell proliferation 
and immune evasion and play a role in cell survival (57,426–428). 
Prenatal exposure to BPA in experimental animals disrupts ERα 
and triggers angiogenesis, and other BPA exposure studies have 
demonstrated that BPA interplays with cell proliferation (226), 
genomic instability (429), inflammation (430) and cell immor-
talization (431). Butyltins, and specifically tributyltin, which is 
suspected to act as an endocrine disruptor, have been found 
to inhibit the cytotoxic activity of NK cells (432), affect inflam-
mation (432) and disrupt membrane metalloproteinases (432). 
Cooperatively, disruption of these processes can lead to prolif-
eration, migration and angiogenesis. Methylmercury (MeHg) is a 
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neurotoxic compound deriving from metallic mercury through 
bacteria-supported metabolism in an aquatic environment. 
Bio-concentration in fish and shellfish poses a risk for sensi-
tive population categories such as pregnant women and infants. 
MeHg-induced ROS production may be involved in inflamma-
tion and apoptosis (433) as well as endothelial cell cytotoxicity 
(434). We also looked at paraquat, which may also have rele-
vance for the tumor microenvironment via its role in oxidative 
stress (435,436).
Avoiding immune destruction
The concept of immune surveillance suggests that the host 
immune system could identify tumor cells and destroy them. 
If this is true, tumor cells need to be poor stimulators of or 
challenging targets for the host immune system. To provide 
an effective immune response, multiple types of the cells are 
involved within innate and adaptive immune ‘arm’ with some 
cells (e.g. DCs and the NK cells) ‘bridging’ these two types 
of immunity (437). To avoid a strong immune response of the 
host, the expression of tumor antigens may be down-regulated 
or altered (resulting in decreased or impossible recognition of 
malignant cells) (438) and various soluble factors and cytokines 
may be released resulting in subverted effectiveness of antitu-
mor immune response (439–441). Tumor cells can also escape 
host immune response by inducing apoptosis in activated T 
cells (442).
Multiple genes involved in immune evasion mechanisms 
and, therefore, can interfere with chemical exposures from 
anthropogenic environment: ADORA1 (adenosine A1 receptor), 
AKT1 (v-akt murine thymoma viral oncogene homolog 1), CCL2 
(chemokine C-C motif ligand 2), CCL26 (chemokine C-C motif 
ligand 26), CD40, CD69, COL3A1 (type III collagen of extracellu-
lar matrix), CXCL10 (also called interferon-inducible protein-10), 
CXCL9 (monokine induced by interferon-γ), EGR1 (early growth 
response protein 1), HIF-1α (hypoxia-inducible factor), IGF1R 
(insulin-like growth factor 1 receptor) and interleukins (IL) such 
as IL-1α and IL-6. Based on available studies, several candi-
date signaling pathways that are related to the host immune 
response can be identified for further study; e.g. the pathways 
involving PI3K/Akt, chemokines, TGF-β, FAK, IGF-1, HIF-1α, IL-6, 
IL-1α, CTLA-4 and PD-1/PDL-1.
Biologically disruptive environmental chemicals can affect 
the host immune responses as follows: (i) if a certain chemical 
is immunotoxic, and, in particular, if it affects activity of DCs, T 
cells or NK cells, it is also likely to affect tumor immuno-surveil-
lance and enable malignant growth to proceed; (ii) if a chemi-
cal targets the immune system, it can increase the cancer risk 
related to other factors/exposures; (iii) exposures to certain tox-
ins or toxicants can dramatically increase the number of can-
cerous cells and impact immuno-regulatory signals suppressing 
the mechanisms of immune control. Collectively, these sorts of 
actions suppress the immune system, so it cannot be effectively 
stimulated and cannot eliminate tumor cells, thus allowing 
some tumor cells to escape and metastasize.
We looked at several groups of environmentally ubiqui-
tous chemicals such as pesticides and personal care products 
that might potentially interrelate with mechanisms of tumor 
immuno-surveillance. Although none of them are recognized as 
human carcinogens (443–445), the research on these chemicals 
and their interactions with the immune response may be valu-
able. For example, the fungicide maneb is a cortisol disruptor 
(446) that has shown a wide spectrum of potential effects on 
multiple pathways, including some that are relevant to immune 
evasion (139,156–158,447). By comparison, pyraclostrobin and 
fluoxastrobin (448) interfere with a narrower spectrum of can-
cer hallmarks (36,449–452). Atrazine has also shown potential 
to impact immune system evasion by directly targeting matura-
tion of DCs and decreasing the levels of major histocompatibility 
complex class I molecules (243,453). The insecticides pyridaben 
and azamethiphos can also both be disruptive to immuno-sur-
veillance (139,140,454,455).
Commonly used in personal care products, triclosan and BPA 
(456), are endocrine disruptors (457–459) that are often detected 
in waters downstream in urban areas (460,461). In addition to 
immune evasion mechanisms (36,142,145), they interfere with 
wide spectrum of cancer-related mechanisms (36,173,429,462–
464). DEHP (472) is also an endocrine disruptor (466,467) that can 
impact multiple hallmarks such as immune evasion, resistance 
to cell death, evasion of antiproliferative signaling, sustained 
proliferative signaling and tumor-promoting inflammation 
(36,288,468,469).
Knowing whether or not cumulative low-dose exposures to 
these chemicals interfere with the host immune response can 
help to stimulate further studies (e.g. on screening of lesions at 
the pre-malignant stage of tumor development) to determine 
the influence of such exposures on host immunity and to evalu-
ate their potential to increase the risk of tumor cell survival.
Dose-response characterizations and LDE
For all the chemicals selected and target sites for disruption that 
were identified, dose-response characterization results and/or 
relevant low-dose research evidence were reviewed and catego-
rized using the criteria mentioned in the Materials and meth-
ods. Table 1 sets out these results and the supporting references.
In total, 85 examples of environmental chemicals were 
reviewed (for specific actions on key pathways/mechanisms that 
are important for carcinogenesis) and 59% of them (i.e. 50/85) 
were found to exert LDE (at levels that are deemed relevant given 
the background levels of exposure that exist in the environment) 
with 15 of the 50 demonstrating their LDE in a non-linear dose-
response pattern. Indeed, all of the teams selected at least one or 
more disruptive chemicals that exerted their effects on the tar-
get sites at low-dose levels. In contrast, only 15% of the chemicals 
reviewed (i.e. 13/85) showed evidence of a threshold.
The remaining 26% of the chemicals reviewed (i.e. 22/85) 
were categorized as ‘unknown’. Some of these chemicals (5 of 
the 22)  had been tested using human primary cell data from 
ToxCast and had showed statistically significant activity across 
a full range of doses against the specified targets (i.e. they 
were active even at the lowest test concentrations of ~0.01 µM). 
However, even though no threshold could be discerned for these 
chemicals, we did not characterize them as having LDE (because 
it was not clear that the lowest test concentrations were low 
enough to be equated to levels of exposure that are normally 
seen in the environment).
Evidence of cross-hallmark relationships
Teams then evaluated the chemicals selected and target sites for 
disruption for known effects on the other cancer hallmark path-
ways. Evidence in the literature that showed procarcinogenic 
actions or anticarcinogenic actions in other hallmark areas were 
reported, and in instances where no literature support was found, 
this was documented as well. The same approach was used for 
the chemicals that were reviewed. A sample of these cross-hall-
mark results is provided in Table  2—Sample of cross-hallmark 
relationships of target pathways/mechanisms and in Table  3—
Cross-hallmark relationships of selected chemical disruptors.
W.H.Goodson et al. | S273
Ta
b
le
 2
. 
Sa
m
p
le
 o
f 
cr
os
s-
h
al
lm
ar
k 
re
la
ti
on
sh
ip
s 
of
 t
ar
ge
t 
p
at
h
w
ay
s/
m
ec
h
an
is
m
s
In
se
n
si
ti
vi
ty
 t
o 
an
ti
gr
ow
th
 s
ig
n
al
s 
(t
ar
ge
ts
)
A
n
ti
gr
ow
th
D
ys
re
g 
m
et
ab
G
en
 in
st
ab
A
n
gi
o
C
el
l d
ea
th
Im
m
u
n
Im
m
or
t
Pr
ol
if
M
et
as
In
fl
am
m
Tu
m
or
 m
ic
ro
PR
O
A
N
T
I
M
IX
p
53
n
/a
+
/−
-
+
/−
−
+
/−
−
−
−
+
+
2
5
3
p
R
B
n
/a
+
/−
−
−
−
0
−
−
−
+
+
2
6
1
T
G
F-
β
n
/a
+
−
+
−
+
−
+
+
+
+
7
3
0
LK
B
1
n
/a
+
−
+
+
/−
0
0
+
−
+
+
5
2
1
C
on
n
ex
in
s
n
/a
−
−
0
0
0
0
−
+
/−
+
+
2
3
1
C
on
ta
ct
 in
h
ib
it
io
n
n
/a
+
/−
−
0
0
+
0
−
−
+
−
2
4
1
O
n
e 
se
t 
of
 r
es
u
lt
s 
(f
ro
m
 t
h
e 
in
se
n
si
ti
vi
ty
 t
o 
an
ti
gr
ow
th
 s
ig
n
al
s 
re
vi
ew
) i
s 
sh
ow
n
 h
er
e 
w
it
h
ou
t 
re
fe
re
n
ce
s 
to
 s
u
p
p
or
t 
a 
d
is
cu
ss
io
n
 o
n
 t
h
e 
ra
n
ge
 o
f 
ef
fe
ct
s 
th
at
 h
av
e 
be
en
 r
ep
or
te
d
 f
or
 t
h
e 
se
le
ct
ed
 t
ar
ge
ts
 in
 e
ac
h
 a
rt
ic
le
. S
p
ec
ifi
c 
re
fe
re
n
ce
s 
su
p
p
or
ti
n
g 
th
es
e 
ef
fe
ct
s 
fo
r 
an
y 
gi
ve
n
 h
al
lm
ar
k 
ar
ea
 c
an
 b
e 
fo
u
n
d
 in
 t
h
e 
in
d
iv
id
u
al
 r
ev
ie
w
s 
w
it
h
in
 t
h
is
 s
p
ec
ia
l i
ss
u
e.
 C
ro
ss
-h
al
lm
ar
k 
re
la
ti
on
sh
ip
s 
ar
e 
re
p
or
te
d
 in
 t
h
e 
fi
rs
t 
11
 c
ol
u
m
n
s 
of
 t
h
e 
ta
bl
e—
ta
bl
e 
 h
ea
d
in
g 
ab
br
ev
ia
ti
on
s 
ar
e 
as
 f
ol
lo
w
s:
ge
n
 in
st
ab
, g
en
et
ic
 in
st
ab
il
it
y;
 d
ys
re
g 
m
et
ab
, d
ys
re
gu
la
te
d
 m
et
ab
ol
is
m
; a
n
ti
gr
ow
th
, i
n
se
n
si
ti
vi
ty
 t
o 
an
ti
gr
ow
th
 s
ig
n
al
s;
 a
n
gi
o,
 a
n
gi
og
en
es
is
; c
el
l d
ea
th
, r
es
is
ta
n
ce
 t
o 
ce
ll
 d
ea
th
; i
m
m
u
n
, a
vo
id
-
in
g 
im
m
u
n
e 
d
es
tr
u
ct
io
n
; i
m
m
or
t,
 r
ep
li
ca
ti
ve
 im
m
or
ta
li
ty
; p
ro
li
f,
 s
u
st
ai
n
ed
 p
ro
li
fe
ra
ti
ve
 s
ig
n
al
in
g;
 m
et
as
, t
is
su
e 
in
va
si
on
 a
n
d
 m
et
as
ta
si
s;
 in
fl
am
m
, t
u
m
or
-p
ro
m
ot
in
g 
in
fl
am
m
at
io
n
; t
u
m
or
 m
ic
ro
, t
u
m
or
 m
ic
ro
en
vi
ro
n
m
en
t.
 T
h
e 
n
u
m
be
r 
of
 p
ro
ca
rc
in
og
en
ic
 (P
R
O
), 
an
ti
ca
rc
in
og
en
ic
 (A
N
T
I)
 a
n
d
 m
ix
ed
 (M
IX
) (
i.e
. p
ro
ca
rc
in
io
ge
n
ic
 a
n
d
 a
n
ti
ca
rc
in
og
en
ic
 r
ep
or
ts
) c
ro
ss
-h
al
lm
ar
k 
re
la
ti
on
sh
ip
s 
fo
r 
ea
ch
 t
ar
ge
t 
h
av
e 
be
en
 s
u
m
m
ed
 a
n
d
 a
re
 r
ep
or
te
d
 in
 t
h
e 
la
st
 t
h
re
e 
co
lu
m
n
s 
of
 t
h
e 
ta
bl
e.
 T
ar
ge
t 
p
at
h
w
ay
s/
m
ec
h
an
is
m
s 
fo
r 
ea
ch
 h
al
lm
ar
k 
ar
ea
 w
er
e 
ev
al
u
at
ed
 b
y 
ea
ch
 t
ea
m
 f
or
 k
n
ow
n
 e
ff
ec
ts
 in
 o
th
er
 c
an
ce
r 
h
al
lm
ar
k 
p
at
h
w
ay
s.
 T
ar
ge
ts
 t
h
at
 w
er
e 
fo
u
n
d
 t
o 
h
av
e 
an
ti
ca
rc
in
og
en
ic
 a
ct
io
n
s 
in
 a
n
ot
h
er
 
h
al
lm
ar
k 
ar
ea
 w
er
e 
in
d
ic
at
ed
 w
it
h
 ‘−
’, 
w
h
er
ea
s 
ta
rg
et
s 
th
at
 w
er
e 
fo
u
n
d
 t
o 
h
av
e 
p
ro
ca
rc
in
og
en
ic
 a
ct
io
n
s 
in
 a
n
ot
h
er
 h
al
lm
ar
k 
ar
ea
 w
er
e 
in
d
ic
at
ed
 w
it
h
 ‘+
’. 
In
 in
st
an
ce
s 
w
h
er
e 
re
p
or
ts
 o
n
 r
el
ev
an
t 
ac
ti
on
s 
in
 o
th
er
 h
al
lm
ar
k 
ar
ea
s 
w
er
e 
m
ix
ed
 (i
.e
. r
ep
or
ts
 s
h
ow
in
g 
bo
th
 p
ro
ca
rc
in
og
en
ic
 p
ot
en
ti
al
 a
n
d
 a
n
ti
ca
rc
in
og
en
ic
 p
ot
en
ti
al
), 
th
e 
sy
m
bo
l ‘
+
/−
’ w
as
 u
se
d
. F
in
al
ly
, i
n
 in
st
an
ce
s 
w
h
er
e 
n
o 
li
te
ra
tu
re
 s
u
p
p
or
t 
w
as
 f
ou
n
d
 t
o 
d
oc
u
m
en
t 
th
e 
re
le
va
n
ce
 o
f 
a 
ta
rg
et
 in
 a
 
p
ar
ti
cu
la
r 
as
p
ec
t 
of
 c
an
ce
r’
s 
bi
ol
og
y,
 w
e 
d
oc
u
m
en
te
d
 t
h
is
 a
s 
‘0
’.
Ta
b
le
 3
. 
C
ro
ss
-h
al
lm
ar
k 
re
la
ti
on
sh
ip
s 
of
 s
el
ec
te
d
 c
h
em
ic
al
 d
is
ru
p
to
rs
In
se
n
si
ti
vi
ty
 t
o 
an
ti
gr
ow
th
 s
ig
n
al
s 
(d
is
ru
p
to
rs
)
A
n
ti
gr
ow
th
D
er
eg
 m
et
ab
G
en
 in
st
ab
A
n
gi
o
C
el
l d
ea
th
Im
m
u
n
Im
m
or
t
Pr
ol
if
M
et
as
In
fl
am
m
Tu
m
or
 m
ic
ro
PR
O
A
N
T
I
M
IX
B
PA
n
/a
+
+
+
+
/−
0
+
+
+
+
0
7
0
1
D
D
T
n
/a
0
+
+
+
+
+
+
0
+
0
7
0
0
Fo
lp
et
n
/a
0
+
0
+
0
0
+
0
+
0
4
0
0
A
tr
az
in
e
n
/a
0
+
0
0
0
0
+
0
+
0
3
0
0
O
n
e 
se
t 
of
 r
es
u
lt
s 
(f
ro
m
 t
h
e 
in
se
n
si
ti
vi
ty
 t
o 
an
ti
gr
ow
th
 s
ig
n
al
s 
re
vi
ew
) i
s 
sh
ow
n
 h
er
e 
w
it
h
ou
t 
re
fe
re
n
ce
s 
to
 s
u
p
p
or
t 
a 
d
is
cu
ss
io
n
 o
n
 t
h
e 
ra
n
ge
 o
f 
ef
fe
ct
s 
th
at
 h
av
e 
be
en
 r
ep
or
te
d
 f
or
 t
h
e 
se
le
ct
ed
 d
is
ru
p
to
rs
 in
 e
ac
h
 r
ev
ie
w
. S
p
ec
ifi
c 
re
fe
re
n
ce
s 
su
p
p
or
ti
n
g 
th
es
e 
ef
fe
ct
s 
fo
r 
an
y 
gi
ve
n
 h
al
lm
ar
k 
ar
ea
 c
an
 b
e 
fo
u
n
d
 in
 t
h
e 
in
d
iv
id
u
al
 r
ev
ie
w
s 
w
it
h
in
 t
h
is
 s
p
ec
ia
l i
ss
u
e.
 C
ro
ss
-h
al
lm
ar
k 
re
la
ti
on
sh
ip
s 
ar
e 
re
p
or
te
d
 in
 t
h
e 
fi
rs
t 
11
 c
ol
u
m
n
s 
of
 t
h
e 
ta
bl
e—
 
ta
bl
e 
h
ea
d
in
g 
ab
br
ev
ia
ti
on
s 
ar
e 
as
 f
ol
lo
w
s:
ge
n
 in
st
ab
, g
en
et
ic
 in
st
ab
il
it
y;
 d
er
eg
 m
et
ab
, d
ys
re
gu
la
te
d
 m
et
ab
ol
is
m
; a
n
ti
gr
ow
th
, i
n
se
n
si
ti
vi
ty
 t
o 
an
ti
gr
ow
th
 s
ig
n
al
s;
 a
n
gi
o,
 a
n
gi
og
en
es
is
; c
el
l d
ea
th
, r
es
is
ta
n
ce
 t
o 
ce
ll
 d
ea
th
; i
m
m
u
n
, 
av
oi
d
in
g 
im
m
u
n
e 
d
es
tr
u
ct
io
n
; i
m
m
or
t,
 r
ep
li
ca
ti
ve
 im
m
or
ta
li
ty
; p
ro
li
f,
 s
u
st
ai
n
ed
 p
ro
li
fe
ra
ti
ve
 s
ig
n
al
in
g;
 m
et
as
, t
is
su
e 
in
va
si
on
 a
n
d
 m
et
as
ta
si
s;
 in
fl
am
m
, t
u
m
or
-p
ro
m
ot
in
g 
in
fl
am
m
at
io
n
; t
u
m
or
 m
ic
ro
, t
u
m
or
 m
ic
ro
en
vi
ro
n
m
en
t.
 
T
h
e 
n
u
m
be
r 
of
 p
ro
ca
rc
in
og
en
ic
 (P
R
O
), 
an
ti
ca
rc
in
og
en
ic
 (A
N
T
I)
 a
n
d
 m
ix
ed
 (M
IX
) (
i.e
. p
ro
ca
rc
in
io
ge
n
ic
 a
n
d
 a
n
ti
ca
rc
in
og
en
ic
 r
ep
or
ts
) c
ro
ss
-h
al
lm
ar
k 
re
la
ti
on
sh
ip
s 
fo
r 
ea
ch
 t
ar
ge
t 
h
av
e 
be
en
 s
u
m
m
ed
 a
n
d
 a
re
 r
ep
or
te
d
 in
 t
h
e 
la
st
 
th
re
e 
co
lu
m
n
s 
of
 t
h
e 
ta
bl
e.
 P
ro
to
ty
p
ic
al
 c
h
em
ic
al
 d
is
ru
p
to
rs
 s
el
ec
te
d
 b
y 
ea
ch
 t
ea
m
 w
er
e 
ev
al
u
at
ed
 f
or
 r
ep
or
te
d
 a
ct
io
n
s 
in
 o
th
er
 c
an
ce
r 
h
al
lm
ar
k 
p
at
h
w
ay
s.
 D
is
ru
p
to
rs
 t
h
at
 w
er
e 
fo
u
n
d
 t
o 
h
av
e 
an
ti
ca
rc
in
og
en
ic
 a
ct
io
n
s 
in
 a
 
p
ar
ti
cu
la
r 
h
al
lm
ar
k 
ar
ea
 w
er
e 
in
d
ic
at
ed
 w
it
h
 ‘−
’, 
w
h
er
ea
s 
d
is
ru
p
to
rs
 t
h
at
 w
er
e 
fo
u
n
d
 t
o 
h
av
e 
p
ro
ca
rc
in
og
en
ic
 a
ct
io
n
s 
in
 a
 p
ar
ti
cu
la
r 
h
al
lm
ar
k 
ar
ea
 w
er
e 
in
d
ic
at
ed
 w
it
h
 ‘+
’. 
In
 in
st
an
ce
s 
w
h
er
e 
re
p
or
ts
 o
n
 r
el
ev
an
t 
ac
ti
on
s 
in
 o
th
er
 
h
al
lm
ar
ks
 w
er
e 
m
ix
ed
 (i
.e
. r
ep
or
ts
 s
h
ow
in
g 
bo
th
 p
ro
ca
rc
in
og
en
ic
 p
ot
en
ti
al
 a
n
d
 a
n
ti
ca
rc
in
og
en
ic
 p
ot
en
ti
al
), 
th
e 
sy
m
bo
l ‘
+
/−
’ w
as
 u
se
d
. F
in
al
ly
, i
n
 in
st
an
ce
s 
w
h
er
e 
n
o 
li
te
ra
tu
re
 s
u
p
p
or
t 
w
as
 f
ou
n
d
 t
o 
d
oc
u
m
en
t 
th
e 
re
le
va
n
ce
 o
f 
a 
ch
em
ic
al
 in
 a
 p
ar
ti
cu
la
r 
as
p
ec
t 
of
 c
an
ce
r’
s 
bi
ol
og
y,
 w
e 
d
oc
u
m
en
te
d
 t
h
is
 a
s 
‘0
’. 
Sp
ec
ifi
c 
re
fe
re
n
ce
s 
su
p
p
or
ti
n
g 
th
es
e 
ef
fe
ct
s 
fo
r 
an
y 
gi
ve
n
 a
re
a 
ca
n
 b
e 
fo
u
n
d
 in
 t
h
e 
in
d
iv
id
u
al
 r
ev
ie
w
s 
in
 t
h
is
 s
p
ec
ia
l i
ss
u
e.
S274 | Carcinogenesis, 2015, Vol. 36, Supplement 1
Ta
b
le
 4
. 
A
gg
re
ga
te
d
 e
vi
d
en
ce
 o
f 
cr
os
s-
h
al
lm
ar
k 
ef
fe
ct
s 
fo
r 
se
le
ct
ed
 p
at
h
w
ay
s/
m
ec
h
an
is
m
s
K
ey
 t
ar
ge
ts
O
ri
gi
n
at
in
g 
re
vi
ew
Pr
oc
ar
ci
n
og
en
ic
A
n
ti
ca
rc
in
og
en
ic
M
ix
ed
A
d
en
os
in
e 
A
1 
re
ce
p
to
r 
(A
D
O
R
A
1)
IS
E
3
1
0
A
h
R
A
n
g
7
0
2
SP
S
7
0
2
B
cl
-2
/p
53
R
C
D
6
2
1
C
el
l c
yc
le
/c
el
l d
iv
is
io
n
: s
p
in
d
le
 d
ef
ec
t
G
I
6
0
1
C
h
ec
kp
oi
n
t 
ki
n
as
e 
1 
an
d
 c
h
ec
kp
oi
n
t 
ki
n
as
e 
2 
(C
h
k1
/2
)
EA
S
4
3
1
C
h
em
ok
in
e 
(C
-C
 m
ot
if
) l
ig
an
d
 2
 (C
C
L2
)
A
n
g
8
1
0
C
h
em
ok
in
e 
(C
--
X
C
 m
ot
if
) l
ig
an
d
 1
0 
(C
X
C
L1
0)
A
n
g
4
1
1
C
h
em
ok
in
e 
(C
--
X
C
 m
ot
if
) l
ig
an
d
 9
 (C
X
C
L9
)
A
n
g
3
2
0
C
h
em
ok
in
e 
si
gn
al
in
g 
p
at
h
w
ay
 (C
C
L2
, C
C
L2
6,
 C
X
C
L9
, C
X
C
L1
0)
IS
E
6
1
2
C
h
ro
n
ic
 o
xi
d
at
iv
e 
st
re
ss
T
M
6
1
1
C
lo
ck
-g
en
es
-m
ed
ia
te
d
 m
et
as
ta
si
s
T
IM
5
1
0
C
ol
la
ge
n
 t
yp
e 
II
I 
(C
O
LI
II
)
A
n
g
3
0
0
C
on
ta
ct
 in
h
ib
it
io
n
EA
S
4
3
0
cS
rc
/H
er
1/
ST
A
T
5B
/E
R
K
1/
2
T
IM
3
1
1
C
yc
li
n
 D
, I
L8
, C
X
C
L
SP
S
4
0
2
C
yc
lo
ox
yg
en
as
e 
ex
p
re
ss
io
n
 a
n
d
 s
ti
m
u
la
ti
on
 c
al
ci
u
m
 s
ig
n
al
in
g 
in
 m
ig
ra
ti
on
.
T
IM
8
1
0
C
yc
lo
ox
yg
en
as
e-
2
T
PI
8
1
0
D
N
A
 d
am
ag
e 
si
gn
al
in
g:
 d
is
tu
rb
ed
 b
y 
R
ed
ox
 s
ig
n
al
in
g 
(N
F-
κB
, N
rf
, E
G
R
)
G
I
8
1
0
D
N
A
 r
ep
ai
r 
p
at
h
w
ay
s
G
I
6
2
1
Ec
k 
fa
tt
y 
ac
id
 m
et
ab
ol
is
m
D
M
6
1
2
El
ec
tr
on
 t
ra
n
sp
or
t 
ch
ai
n
 c
om
p
le
xe
s 
II
 a
n
d
 I
V
D
M
3
2
0
Ep
id
er
m
al
 g
ro
w
th
 f
ac
to
r 
re
ce
p
to
r
SP
S
6
0
1
Ep
ig
en
et
ic
 p
at
h
w
ay
s
 
D
is
tu
rb
ed
 m
iR
N
A
 b
in
d
in
g
G
I
6
0
2
 
D
N
A
 m
et
h
yl
at
io
n
G
I
7
0
1
 
H
is
to
n
e 
ac
et
yl
at
io
n
G
I
6
1
1
EM
T
T
IM
5
0
1
EM
T,
 c
at
en
in
-W
n
t 
p
at
h
w
ay
T
IM
6
1
1
Er
bB
-2
/H
ER
-2
 t
yr
os
in
e 
ki
n
as
e
R
C
D
6
1
0
ER
K
/M
A
PK
R
C
D
8
2
0
Es
tr
og
en
 r
ec
ep
to
r
T
PI
5
3
1
Es
tr
og
en
 r
ec
ep
to
r 
α
 (b
in
d
in
g 
to
)
R
C
D
5
1
1
G
ap
 ju
n
ct
io
n
 c
on
n
ex
in
s
EA
S
2
2
2
G
JI
C
R
C
D
2
1
1
G
lu
co
n
eo
ge
n
es
is
D
M
5
3
0
G
ly
co
ly
si
s
D
M
8
1
0
H
ex
ok
in
as
e 
2
D
M
6
1
0
H
-R
as
SP
S
6
1
2
H
yp
er
se
cr
et
io
n
 o
f 
lu
te
in
iz
in
g 
h
or
m
on
e 
by
 g
on
ad
ot
ro
p
h
 c
el
ls
 in
 p
it
u
it
ar
y 
gl
an
d
R
C
D
2
1
0
H
IF
-1
-α
 p
at
h
w
ay
IS
E
8
0
2
In
d
u
ci
bl
e 
n
it
ri
c 
ox
id
e 
sy
n
th
as
e
T
PI
6
1
0
IG
F-
1 
si
gn
al
in
g 
p
at
h
w
ay
IS
E
6
2
1
In
te
rc
el
lu
la
r 
ad
h
es
io
n
 m
ol
ec
u
le
 1
 (I
C
A
M
1)
A
n
g
6
3
0
W.H.Goodson et al. | S275
K
ey
 t
ar
ge
ts
O
ri
gi
n
at
in
g 
re
vi
ew
Pr
oc
ar
ci
n
og
en
ic
A
n
ti
ca
rc
in
og
en
ic
M
ix
ed
IL
-6
T
PI
7
0
0
IL
-6
 e
xp
re
ss
io
n
, i
m
p
ro
p
er
 D
C
 m
at
u
ra
ti
on
 a
n
d
 p
ol
ar
iz
at
io
n
T
M
5
2
0
Ju
n
/F
os
/A
P1
SP
S
4
1
3
Li
p
id
 m
et
ab
ol
is
m
/c
h
ol
es
te
ro
l m
et
ab
ol
is
m
D
M
4
2
1
Li
ve
r 
ki
n
as
e 
B
1 
(L
kb
1)
EA
S
4
2
2
M
M
P 
1
A
n
g
6
1
0
M
M
P-
9 
ac
ti
va
ti
on
T
IM
5
1
1
M
it
oc
h
on
d
ri
al
 f
u
n
ct
io
n
G
I
5
2
2
M
A
PK
R
C
D
9
0
1
m
T
O
R
 a
ct
iv
at
io
n
D
M
7
1
1
m
T
O
R
 in
ac
ti
va
ti
on
R
I
3
6
1
N
K
 c
el
l i
n
h
ib
it
io
n
T
M
4
3
0
N
F-
κB
T
PI
4
2
0
O
xi
d
at
iv
e 
st
re
ss
 a
n
d
 I
L-
6 
p
ro
d
u
ct
io
n
T
M
3
1
1
P1
6/
p
53
R
C
D
4
4
0
P5
3 
in
ac
ti
va
ti
on
EA
S
10
0
0
R
C
D
10
0
0
R
I
10
0
0
PP
A
R
SP
S
5
2
0
PP
A
R
-α
R
C
D
3
3
1
PI
3K
/A
kt
 s
ig
n
al
in
g 
p
at
h
w
ay
IS
E
9
0
1
Py
ru
va
te
 d
eh
yd
ro
ge
n
as
e 
(P
D
H
)
D
M
1
5
0
R
O
S 
(i
n
cr
ea
se
)
D
M
6
0
4
R
O
S 
an
d
 c
el
lu
la
r 
st
re
ss
T
M
5
0
4
R
et
in
ob
la
st
om
a 
p
ro
te
in
 (p
R
b)
 in
ac
ti
va
ti
on
EA
S
9
0
0
R
I
9
0
0
St
er
oi
d
 h
or
m
on
e 
re
ce
p
to
rs
SP
S
5
0
1
Te
lo
m
er
as
e 
ac
ti
va
ti
on
R
I
9
1
0
Te
lo
m
er
e 
lo
ss
G
I
4
4
0
T
h
e 
tr
ic
ar
bo
xy
li
c 
ac
id
 c
yc
le
D
M
5
4
0
T
h
ro
m
bo
m
od
u
li
n
A
n
g
2
3
0
Tr
an
sf
or
m
in
g 
gr
ow
th
 f
ac
to
r 
β
EA
S
6
3
1
Tu
m
or
 n
ec
ro
si
s 
fa
ct
or
 α
T
PI
8
0
1
U
ro
ki
n
as
e 
re
ce
p
to
r 
(u
PA
R
)
A
n
g
6
2
0
V
as
cu
la
r 
ce
ll
 a
d
h
es
io
n
 m
ol
ec
u
le
 1
 (V
C
A
M
1)
A
n
g
6
0
0
A
gg
re
ga
te
d
 n
u
m
be
r 
of
 p
ro
ca
rc
in
og
en
ic
 a
ct
io
n
s,
 a
n
ti
ca
rc
in
og
en
ic
 a
ct
io
n
s 
an
d
 in
st
an
ce
s 
w
h
er
e 
m
ix
ed
 a
ct
io
n
s 
(i
.e
. p
ro
ca
rc
in
io
ge
n
ic
 a
n
d
 a
n
ti
ca
rc
in
og
en
ic
) w
h
er
e 
cr
os
s-
h
al
lm
ar
k 
ef
fe
ct
s 
h
av
e 
be
en
 r
ep
or
te
d
 (f
or
 e
ac
h
 p
at
h
w
ay
/
m
ec
h
an
is
m
 a
cr
os
s 
th
e 
fu
ll
 r
an
ge
 o
f 
h
al
lm
ar
k 
d
om
ai
n
s—
i.e
. f
ro
m
 a
ll
 o
f 
th
e 
ar
ea
s 
co
ve
re
d
 b
y 
th
e 
re
vi
ew
s 
in
 t
h
is
 s
p
ec
ia
l i
ss
u
e)
—
se
e 
sa
m
p
le
s 
of
 t
h
is
 d
at
a 
in
 T
ab
le
 2
. N
ot
e:
 f
u
ll
y 
re
fe
re
n
ce
d
 d
at
a 
fo
r 
th
es
e 
cr
os
s-
h
al
lm
ar
k 
ef
fe
ct
s 
ca
n
 
be
 f
ou
n
d
 in
 e
ac
h
 o
f 
th
e 
re
vi
ew
s 
in
 t
h
is
 s
p
ec
ia
l i
ss
u
e.
 A
N
G
, a
n
gi
og
en
es
is
; D
M
, d
ys
re
gu
la
te
d
 m
et
ab
ol
is
m
; E
A
S,
 e
va
si
on
 o
f 
an
ti
gr
ow
th
 s
ig
n
al
in
g;
 G
I, 
ge
n
et
ic
 in
st
ab
il
it
y;
 I
SE
, i
m
m
u
n
e 
sy
st
em
 e
va
si
on
; R
C
D
, r
es
is
ta
n
ce
 t
o 
ce
ll
 d
ea
th
; R
I, 
re
p
li
ca
ti
ve
 im
m
or
ta
li
ty
; S
PS
, s
u
st
ai
n
ed
 p
ro
li
fe
ra
ti
ve
 s
ig
n
al
in
g;
 T
IM
, t
is
su
e 
in
va
si
on
 a
n
d
 m
et
as
ta
si
s;
 T
M
, t
u
m
or
 m
ic
ro
en
vi
ro
n
m
en
t;
 T
PI
, t
u
m
or
-p
ro
m
ot
in
g 
in
fl
am
m
at
io
n
.
Ta
b
le
 4
. 
C
on
ti
nu
ed
S276 | Carcinogenesis, 2015, Vol. 36, Supplement 1
Note that Tables 2 and 3 contain just a single set of unref-
erenced results from the review on the hallmark insensitivity to 
antigrowth signals. This is intended only to illustrate the catego-
ries of cross-hallmark effects that were reviewed and to show 
how they were presented. Fully referenced results for each hall-
mark area can be found in each of the individual reviews within 
this special issue.
The decision to review target sites for disruption and proto-
typical disruptors for cross-hallmark effects was driven by the 
fact that many individual studies and reviews of chemical expo-
sures fail to account systematically for the spectrum of inci-
dental actions that can result from exposures to a single given 
chemical. It was our belief that this approach constitutes a bet-
ter way to ensure that we had assembled a reasonably complete 
view of the literature (i.e. where any sort of evidence of cross-
hallmark activity had been reported). Future research will likely 
involve empirical testing of mixtures, so we wanted to create a 
heuristic that could serve as a starting point for other research-
ers who might be considering such research.
For researchers focused on low-dose exposure research 
intended to produce carcinogenesis, we anticipated that there 
would be interest in chemicals that had been reported to exhibit 
a large number of procarcinogenic actions across a number of 
hallmarks and we anticipated that a lack of anticarcinogenic 
potential would be important to identify (as targets or approaches 
that exert anticarcinogenic actions would potentially represent 
a confounding influence/factor in empirical research aimed at 
the identification of carcinogenic synergies). To that end, Table 4 
provides a summary of the aggregated number of procarcino-
genic actions, anticarcinogenic actions and instances where 
mixed actions (i.e. procarciniogenic and anticarcinogenic) have 
been found for each pathway/mechanism (across the full range 
of hallmark domains—i.e. from all of the areas covered by the 
reviews in this special issue). Similarly, Table 5 provides a sum-
mary of the aggregated number of procarcinogenic actions, 
anticarcinogenic actions and mixed actions (i.e. procarcinogenic 
and anticarcinogenic), where cross-hallmark effects have been 
reported for each chemical (across the full range of hallmark 
domains—i.e. from all of the areas covered by the reviews in this 
special issue).
Note that, in some instances, the underlying evidence used 
to support the indication of cross-hallmark relationships was 
robust, consisting of multiple studies involving detailed in-vitro 
and in-vivo findings. In other instances, the underlying evidence 
that was used to report the existence of a cross-hallmark rela-
tionship was quite weak (e.g. consisting of only a single in-vitro 
study involving a single cell-type). The selected prototypical dis-
ruptors are likely biased towards agents that have been exten-
sively studied, and not necessarily those that will prove to be 
the most important biologically. Finally, there are examples of 
chemicals that are known to exert different effects at different 
dose levels, but dose levels were not used to discriminate when 
gathering evidence of cross-hallmark effects. So, the referenced 
cross-validation results in the individual tables (reported in the 
many reviews within this special issue) should be seen only as 
a starting point for those who are pursuing mixtures research 
(e.g. references would need to be further scrutinized to deter-
mine whether or not the dose levels noted for specific results 
are suitable points of reference for the type of research that is 
being undertaken).
Particular attention should also be given to results related to 
the endocrine system due to mechanistic complexity. For exam-
ple, xeno-estrogen compounds are typically compared with 
estradiol based on binding affinity strength. However, many 
xeno-estrogens that are ‘weak’ by this measure can alter the 
steroidogenic cascade (e.g. significantly up-regulate the activ-
ity of P450 aromatase, the enzyme that increases intracellular 
estradiol synthesis within estrogen-sensitive cells (470–473) or 
alter levels of ERα or the ratio of ERα:ERβ (260)). In other words, a 
weak xeno-estrogen can stimulate the production of estradiol, a 
potent endogenous carcinogen (474) or alter the receptors with 
which a cell will respond to estrogen.
Nonetheless, given that the overarching goal in this project 
was to create a foundation that would allow researchers to look 
systematically across the literature in each of these areas, the 
tables should serve as a useful starting point as long as they 
are approached with these caveats in mind. We believe that 
this heuristic will be useful to consider synergies that might be 
anticipated in testing that involves certain target sites for dis-
ruption and/or mixtures of chemical constituents that are being 
considered for procarcinogenic effects. Future research efforts 
to improve this approach could involve a large-scale collabora-
tive effort to generate high-quality in-vitro data and low-dose in-
vivo data in a range of predefined tissues.
Discussion
Getting to Know Cancer hosted the initial project meeting in 
Halifax, Nova Scotia giving participants an opportunity to have 
presentations, break-out sessions, and chances for conversation 
and debate among experts who came from a range of different 
disciplines. Cancer biologists with specialized expertise in areas 
related to individual hallmarks met with specialists from other 
areas such as environmental health, toxicology and endocrinol-
ogy. Although some researchers in the field of environmental 
health are cancer scientists in their own right, many conference 
participants commented on the novelty of having an oppor-
tunity to work so closely with cancer biology specialists. As a 
result, many interdisciplinary barriers were removed and the 
discussions that ensued were challenging but productive.
At the outset, participants overwhelmingly agreed that the 
Hallmarks of Cancer provides a useful organizing heuristic for 
systematic review of ways that biologically disruptive chemicals 
might exert procarcinogenic and anticarcinogenic influences in 
biological systems. Most of the individual writing teams were 
then readily able to identify ubiquitous environmental contami-
nants with disruptive potential in their respective areas of study. 
The only teams that had significant challenges in this regard 
were the ones that focused on the bypassing of senescence (i.e. 
replicative immortality) and dysregulated metabolism, both being 
areas of cancer research that have not yet received a lot of atten-
tion from researchers in the field of toxicology.
Considerable discussion was devoted to the criteria that 
were used to select prototypical disruptors from the long list of 
known potential contaminants. Indeed, it seems that much of 
the population is now exposed to a wide variety of exogenous 
chemicals that have some disruptive potential, but we did not 
have any intention of implicating any of the selected chemicals 
as being carcinogenic per se. It was simply agreed that chemi-
cals would be chosen that met the basic criteria and that then 
could be used as ‘prototypical’ disruptors. In other words, the 
chemicals that were selected for this review were not deemed to 
be the most important, and they were not selected to somehow 
imply (based on current information) that they are endanger-
ing us. Rather, we simply wanted to illustrate that many non-
carcinogenic chemicals (that are ubiquitous in the environment) 
have also been shown to exert effects at low doses, which are 
highly relevant to the process of carcinogenesis. We also wanted 
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Table 5. Aggregated evidence of cross-hallmark effects for selected chemical disruptors
Chemicals Originating review Procarcinogenic Anticarcinogenic Mixed
12-O-Tetradecanoylphorbol-13-acetate SPS 5 1 0
HPTE ANG 4 0 0
Acetaminophen RI 0 4 2
Acrolein DM 3 3 3
Acrylamide GI 3 1 1
Atrazine ISE 3 0 1
EAS 4 0 1
TPI 3 0 1
Azamethiphos ISE 1 0 0
Benomyl GI 0 3 1
Benzo(a)pyrene SPS 8 1 0
Biorhythms TIM 3 2 0
Biphenyl ANG 2 2 1
BPA EAS 6 0 1
GI 6 0 1
ISE 7 0 1
RCD 7 0 0
SPS 6 0 1
TIM 7 0 1
TM 7 0 1
TPI 6 0 1
Bisphenol AF ANG 5 1 0
Butyltins (such as tributyltin) TM 4 2 0
C.I. solvent yellow 14 ANG 4 0 0
Carbendazim GI 0 2 1
Carbon black GI 5 1 0
Chlorothalonil ANG 5 1 0
RCD 5 0 0
Cobalt GI 5 2 0
Copper DM 6 0 3
Cotinine RI 4 1 0
Cypermethrin DM 5 0 0
DDT EAS 6 0 0
Diazinon DM 2 3 0
Dibutyl phthalate RCD 4 0 0
Dichlorvos RCD 4 0 0
DEHP ISE 4 0 1
RCD 4 0 0
Diniconazole ANG 2 0 0
Fluoxastrobin ISE 2 1 0
Folpet EAS 2 1 0
Hexachlorobenzene TIM 5 2 0
Hexythiazox DM 0 0 0
Imazalil SPS 3 1 0
Iron DM 5 1 3
TIM 5 1 2
Lactofen SPS 2 0 0
Lead GI 3 1 0
RI 3 1 0
Lindane RCD 5 0 0
Linuron RCD 2 0 0
Malathion DM 5 0 0
Maneb ISE 4 2 0
Mercury GI 3 2 1
MXC RCD 3 0 0
Methylene bis(thiocyanate) ANG 2 1 0
MeHg TM 5 2 0
Na-selenite RI 0 4 2
Nickel GI 6 1 1
TM 6 1 1
Nickel chloride RI 6 0 2
Nitric oxide RI 5 2 2
4-NP TPI 2 1 0
Oxyfluorfen RCD 4 0 0
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to lay out a heuristic framework that would be helpful for other 
researchers who are interested in considering these and other 
chemicals as potential constituents for low-dose mixtures 
research.
LDE, chemical mixtures and carcinogenicity
Although we did not specifically ask the teams to focus on 
disruptive chemicals that were known to exert LDE, the sum-
mary of dose-response characterizations for the chemicals 
that were selected by these teams is dominated by chemi-
cals (i.e. 50/85) that have been shown to produce LDE, and 
15 of the 50 showed evidence of a non-linear dose-response. 
Surprisingly, only 15% of the chemicals reviewed (i.e. 13/85) 
showed evidence of a threshold. We believe that this helps to 
validate the idea that chemicals can act disruptively on key 
cancer-related mechanisms at environmentally relevant lev-
els of exposure.
Historically, the axiom ‘the dose makes the poison’ has had 
some merit, so many people remain skeptical about the idea 
that adverse outcomes can result from minute exposures to 
commonly encountered chemicals. But we are now at a point in 
time where our knowledge of the biology of cancer has advanced 
considerably, and we know that carcinogenesis can begin when 
key events have occurred in a single cell, between cells or in 
the surrounding microenvironment. So the idea that LDE from 
many environmental chemicals (acting together) might serve 
to instigate, support or fully enable carcinogenesis, no longer 
appears to be an unreasonable assertion.
At this stage, we are not making any assumptions about 
whether or not future empirical research will find support for 
this hypothesis, nor are we assuming that this a significant 
problem. We are simply impressed by the fact that we are now 
starting to see evidence of a wide range of LDE (that are directly 
related to carcinogenesis) that can be exerted by chemicals that 
are ubiquitous and unavoidable in the environment. As a result, 
we are compelled to explore and consider this possibility.
In-utero exposures and transgenerational effects
Additionally, a number of the teams cited in-utero exposure 
studies in their reviews and presented evidence on transgen-
erational effects. Although this detail is not fully captured in 
the team summaries offered in this capstone paper (please see 
the individual reviews in this special issue for complete details), 
these effects are important to acknowledge. For example, the 
inflammation team noted that transient early life exposures in 
utero to vinclozolin have been linked to both adult-onset dis-
ease and transgenerational disease that involves inflamma-
tion. Similarly, the immune system evasion team reported that 
there is increasing evidence from animal studies that in-utero 
or neonatal exposures to BPA are associated with higher risk of 
immune system dysregulation that may develop later in life.
Taken together, these and other similar types of examples 
raise intriguing possibilities about vulnerabilities at the popu-
lation level, and the contributions that in utero and early life 
exposures to mixtures of those chemicals might make towards 
cancer susceptibility. Single-generation experimental models 
are inadequate to detect this sort of disruptive activity (for expo-
sures to a given chemical or to mixtures of chemicals), but these 
sorts of effects may increase cancer risks by promoting and/or 
enabling tumorigenesis.
The interplay between genetic factors and 
environmental factors
Given the number of key cancer-related mechanisms that can 
apparently be disrupted by chemicals that are commonly found 
in the environment, and the possibility that in-utero and/or early 
life exposures may also contribute to population vulnerabil-
ity, the interplay between genetic factors and environmental 
Chemicals Originating review Procarcinogenic Anticarcinogenic Mixed
Paraquat GI 4 2 0
TM 4 2 0
PFOS ANG 4 1 0
SPS 4 1 0
Phosalone SPS 1 1 0
Phthalates TIM 6 0 1
TPI 6 0 1
PBDEs TPI 2 0 2
Pyraclostrobin ISE 2 1 0
Pyridaben ISE 1 3 1
Quinones GI 1 6 1
Rotenone DM 2 5 1
Sulfur dioxide TIM 5 1 0
Titanium dioxide NPs GI 3 1 1
Tributyltin chloride ANG 3 1 0
Triclosan GI 2 2 1
ISE 3 2 1
Tungsten GI 2 1 1
Vinclozolin TPI 2 1 0
Ziram ANG 3 1 1
Aggregated number of procarcinogenic actions, anticarcinogenic actions and mixed actions (i.e. procarciniogenic and anticarcinogenic) where cross-hallmark effects 
have been reported (for each chemical across the full range of hallmark domains—i.e. from all of the areas covered by the reviews in this special issue)—see samples 
of this how this data were reported in Table 3. Note: fully referenced data for these cross-hallmark effects can be found in each of the reviews in this special issue. 
ANG, angiogenesis; DM, dysregulated metabolism; EAS, evasion of antigrowth signaling; GI, genetic instability; ISE, immune system evasion; RCD, resistance to cell 
death; RI, replicative immortality; SPS, sustained proliferative signaling; TIM, tissue invasion and metastasis; TM, tumor microenvironment; TPI, tumor-promoting 
inflammation.
Table 5. Continued
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factors should also be mentioned. For example, a hereditary 
genetic vulnerability (such as mutations to BRCA1/2 genes 
which greatly increase the lifetime risk of breast and ovarian 
cancer (482)) can predispose someone to a higher risk of cancer. 
But many hereditary genetic mutations and somatic mutations 
do not result in cancer, presumably because additional actions 
(e.g. sustained proliferative signaling) are needed or additional 
biological safeguards still need to be suppressed or defeated 
(e.g. apoptosis, senescence, immuno-surveillance and so on) 
before a fully immortalized cellular phenotype can emerge. In 
these instances, cancer may not be assured, but it is easy to 
see how the disruptive effects of low-dose exposures to certain 
chemicals might act on key pathways/mechanisms and play a 
supporting role in the steps involved in carcinogenesis and/or 
increase the overall risk of getting cancer.
This same issue applies to other sensitive subpopulations 
who might be predisposed to higher levels of cancer risk. In some 
instances, vulnerabilities that exist are genetic in nature (e.g. 
cancer patients in remission), due to endogenous factors (e.g. 
due to obesity) or due to external influences (i.e. smoking). But 
in all cases, the enhanced risks in these subpopulations leave 
the affected individuals vulnerable to carcinogenesis. Although 
a detailed investigation of this type of interaction is beyond the 
scope of this project, it is important to consider that low dose, 
disruptive chemical effects on key pathways and mechanisms 
in these subpopulations may serve to further enhance cancer 
susceptibility, or even fully enable carcinogenesis.
The low-dose carcinogenesis hypothesis
It is important to reiterate that this group has no interest in 
implicating any of the chemicals that were reviewed in this 
project as individual carcinogens per se. We fully realized 
at the outset that much of the evidence in the toxicological 
literature that documented the disruptive actions of these 
chemicals had been produced under a wide range of differing 
experimental circumstances. So it was agreed at the beginning 
that we would not make leaps between different lines of evi-
dence nor draw any specific conclusions about chemical mix-
tures that might prove to be carcinogenic. Nonetheless, we are 
intrigued by the number of chemicals that we reviewed that 
were found to be capable of disruptive LDE on key pathways/
mechanisms across all of the areas that were reviewed. Many 
of the environmental chemicals that we chose are well known 
as environmental contaminants, but they represent only a 
small fraction of the thousands of chemicals that are now 
ubiquitous and unavoidable in the environment. So although 
we cannot draw any firm conclusions at this stage, we emerge 
from this effort with a better understanding of the evidence 
that is available to support the merits of our initial hypothesis 
(i.e. that low-dose exposures to disruptive chemicals that are 
not individually carcinogenic may be capable of instigating 
and/or enabling carcinogenesis).
Although the breadth and scope of this review effort was 
daunting, we now believe that we have enough supporting evi-
dence to offer a holistic overview of this issue. At a minimum, 
we hope that the studies cited in this review, the gaps that we 
have identified and the framework that we have proposed for 
future research will be useful to researchers who are encour-
aged to explore this hypothesis in greater detail.
The implications for risk assessment
Thirty-five years ago, the work of Ames and others who fol-
lowed set in motion a quest for individual chemicals as (com-
plete) ‘carcinogens’ that became a dominant paradigm that has 
shaped our thinking for decades (226). So dominant has the 
focus been on single chemicals, that combinations of chemi-
cals are rarely tested or even considered. For example, although 
IARC has focused on extensive monographs of the carcinogenic 
nature of individual chemicals, little has been done to evaluate 
the possibility of carcinogenic effects attributable to chemical 
mixtures except in a few instances where mixtures of concern 
are encountered during occupational exposures (e.g. polychlo-
rinated dibenzo-p-dioxins and polychlorinated dibenzofurans) 
or as a result of personal and cultural habits (e.g. cigarette 
smoke, diesel and gasoline engine exhausts).
But the search for mutagenic carcinogens was never 
matched with a corresponding search for chemicals that might 
contribute to the promotion of carcinogenesis along with other 
chemicals. We now know that individual chemicals can produce 
unique disruptions of cellular biology and specific combinations 
of non-carcinogenic chemicals have been able to demonstrate 
potent carcinogenic effects. Yet, we have only scratched the sur-
face of the biology of mixtures, and we need to look carefully at 
the synergistic effects.
In risk assessments, the risks associated with exposures to 
mixtures of chemicals are often estimated using relatively sim-
ple, component-based approaches (476). Risk analysts evalu-
ate information regarding the mode of action associated with 
individual mixture components and then use either ‘dose addi-
tion’ or ‘response addition’ to predict effects. Dose addition is 
an appropriate approach to assess mixtures risks, when the 
chemicals of interest act through a common mode of action. 
Although response addition assumes that constituent agents 
act independently of each other (cause the same outcome via 
different modes of action). In general, a dose addition approach 
would be appropriate for mixtures risk assessment if we wanted 
to consider a series of chemicals that were carcinogenic in their 
own right, and if they all produced the cancer by the same mode 
of action. The Hallmarks of Cancer framework suggests that 
we should be equally, if not more, concerned about mixtures of 
chemicals that are not individually carcinogenic but disruptive 
in a manner that is collectively procarcinogenic (i.e. potentially 
capable of producing carcinogenic synergies when combined 
with other chemicals that are acting on the diverse series of 
mechanisms involved in carcinogenesis).
With this in mind, there should be concern that the World 
Health Organization International Programme on Chemical 
Safety (WHO IPCS) has spent the past decade developing a 
risk analysis agenda predicated mainly on a ‘Mode of Action’ 
framework (477–480), where ‘mode of action’ is defined as a 
sequence of key events and processes, starting with interaction 
of an agent with a cell, proceeding through operational and ana-
tomical changes and resulting in an adverse outcome, in this 
case, cancer formation. The OECD guidance on the conduct and 
design of chronic toxicity and carcinogenicity (which is followed 
by many nations) now also reflects this approach (480). This 
analysis of risks from cumulative effects of chemical exposures 
is restrictive because it suggests that regulators should only 
focus on groupings of individual chemicals that are as follows:
(a)  known to act via a common sequence of key events and 
processes;
(b)  known to act on a common target/tissue and
(c)  known to produce a common adverse outcome (e.g. 
cancer).
So, for example, in the USA, the Food Quality Protection Act pro-
vides legislated guidance on testing for cumulative effects by 
using the term ‘common mechanism of toxicity’ (481), which is 
interpreted to mean ‘mode of action’ or ‘the major steps leading 
to an adverse health effect following interaction of a pesticide 
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with biological targets’. Similarly, in Canada, the Pest Control 
Products Act requires the government to assess the cumulative 
effects of pest control products that have a ‘common mecha-
nism of toxicity’. In the USA, there has also been a tradition of 
employing an additional restriction requiring chemical struc-
tural similarity when selecting groups of chemicals to be sub-
jected to mixtures risk assessment (other than a few instances 
where whole mixtures have been assessed, e.g. diesel exhaust, 
combinations of chemicals that are not similar structurally have 
been largely ignored (489)). In light of current knowledge of can-
cer biology, these criteria appear to be inappropriately restric-
tive, and thus demand a number of considerations—as follows:
Cumulative risk assessment should anticipate synergies of chemicals 
acting via dissimilar sequences/processes. From the Hallmarks of 
Cancer framework, it becomes evident that chemicals that act 
via dissimilar pathways/targets or that produce different sorts 
of key events and/or employ different processes could very 
well produce synergies within carcinogenesis that would be 
relevant for cumulative risk assessment purposes. For example, 
ethylenediaminetetraacetic acid (EDTA) is a ubiquitous, 
presumably non-carcinogenic chemical that disrupts DNA 
repair (483,484), and it is well established that it influences 
chromosome breakage by mutagenic agents. In particular, 
when applied in combination with chemical mutagens, EDTA 
enhances mutagen-induced aberration frequencies and 
contributes to genetic instability (485). But within the mode of 
action framework, a chemical that is a mutagenic carcinogen, 
would not be assessed for the cumulative risks associated with 
an additional exposure to a chemical that disrupts DNA repair (a 
key layer of cancer defense) because it is not known to produce 
a common sequence of key events and processes.
A 2008 report on phthalates and cumulative risk assess-
ment emphasized that the chemicals considered for cumula-
tive risk assessment should be ones that cause the same health 
outcomes or the same types of health outcomes, not ones that 
cause the health outcomes only by a specific pathway (486). 
Similarly, The European Food Safety Authority Panel on Plant 
Protection Products and their Residues (PPR Panel) produced a 
scientific opinion on the relevance of dissimilar modes of action 
and their relevance for cumulative risk assessment of pesticides 
residues in food (482). The PPR Panel found good evidence that 
combination effects can arise from co-exposure to chemicals 
that produce common (adverse) outcomes through entirely 
different modes of action and recommended cumulative risk 
assessment methods to evaluate mixtures of pesticides in foods 
that have dissimilar modes of action (396).
Cumulative risk assessment should anticipate synergies of chemicals 
acting on different targets/tissues. The Hallmarks of Cancer 
framework suggest that spatiotemporal aspects of chemical 
exposures are likely important as well. For example, the many 
constituent parts of the immune system and its distributed 
nature (e.g. lymph vessels, thymus, bone marrow and so on), the 
hypothalamic–pituitary–adrenal axis and cortisol in circulation, 
which are used to suppress macrophage migration inhibitory 
factor and control inflammation (487–489) and the surrounding 
tissues of the tumor microenvironment, are all relevant targets 
that could be chemically disrupted to produce procarcinogenic 
contributions to carcinogenesis.
For example, as noted previously, maneb is a fungicide with 
a potentially disrupting effect on cortisol (446), which could 
impact the body’s response to inflammation suppression, 
whereas atrazine affects the host immune response by directly 
targeting maturation of DCs and decreasing the levels of major 
histocompatibility complex class  I  molecules (243,453). Both 
are highly relevant forms of disruption for carcinogenesis, but 
within the mode of action framework, the cumulative effects 
of these chemicals (and other chemicals acting on these and 
similarly distributed targets) would never be assessed together 
because they do not act on a common biological target.
The PPR Panel recently pointed out that there is no empiri-
cal evidence for the validity of independent action as a predic-
tive concept for multicomponent mixtures in the mammalian 
toxicological literature. Further, they argued that although over-
lapping toxic effects in different organs/systems may exist, it is 
difficult to identify a combination effect. Thus, the panel specifi-
cally restricted their focus to chemicals that ultimately produce 
a common adverse outcome (e.g. cancer) in the same target 
organ/system (482). Although it may be difficult to identify this 
sort of an effect, that does not mean, however, that we should 
ignore this possibility (i.e. now that our understanding of the 
biology of cancer has improved).
Cumulative risk assessment should anticipate synergies of non-
carcinogens. The WHO IPCS mode of action framework accepts 
the notion of a common toxic endpoint and therefore that 
chemicals need to first be carcinogens themselves before they 
can be considered as possible constituents of carcinogenic 
mixtures. However, it is now evident that not every 
procarcinogenic action resulting from a chemical exposure 
must be the result of a chemical that is a carcinogen itself. 
Continued focus on individual carcinogens reflects a lingering 
paradigm that overlooks the examples of synergies such as 
those highlighted in this project. Low-dose mechanistic 
effects may be very important so approaches are needed 
that take this into account. In chronic and complex diseases, 
establishing dose thresholds using the whole disease as the 
endpoint (e.g. cancer) may be inappropriate, especially when 
exposures to individual chemicals can produce relevant (but 
not disease causing) mechanistic effects at much lower dose 
levels. 
Cumulative risk assessment should anticipate synergies of 
structurally dissimilar chemicals. The EPA’s emphasis on 
structurally similar classes of chemicals for mixtures risk 
assessments is unnecessarily restrictive. The dissimilar 
chemicals reviewed within this special issue are testament to 
the fact that similar disruptive effects can be produced by a wide 
range of chemical structures and failure to adapt testing to this 
fact is no longer acceptable (486).
In sum, it is concerning that the WHO IPCS approach is so 
highly restrictive when it comes to the assessment of cumu-
lative effects. The OECD guidelines acknowledge that cancers 
originating from at least some cell types may arise by a vari-
ety of independent pathways, but the guidance is fundamen-
tally focused on the identification of individual carcinogens and 
cumulative effects of carcinogens, specifically noting that the 
approach is intended to ‘avoid misidentification of non-tumorigenic 
compounds as possible human carcinogens’ (480). But in practice, as 
in-vitro and in-vivo evidence for many chemicals is frequently 
not available (i.e. to prove that they individually act via a com-
mon sequence of key events or process a common target/tissue 
to produce cancer), it means that risk assessments of the cumu-
lative effects of exposures to mixtures of chemicals on carcino-
genesis are rarely conducted.
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The International Life Sciences Institute, which is a non-
profit organization with members comprised largely of major 
corporate interests from the food and beverage, agricultural, 
chemical and pharmaceutical industries, has worked closely 
with the WHO IPCS to support this approach. But while it may 
serve to ensure the avoidance of the misidentification of (non-
tumorigenic) chemicals/compounds as possible human car-
cinogens, it simultaneously discourages regulatory agencies 
from exploring the sorts of synergies that might plausibly be 
expected to occur. Indeed, the biology of cancer suggests that 
the cumulative effects of non-carcinogenic chemicals acting on 
different pathways that are relevant to cancer, and on a variety 
of cancer-relevant systems, organs, tissues and cells may very 
well conspire to produce carcinogenic synergies that will be 
overlooked entirely as long as the mode of action framework 
(and the restrictions that it imposes) remains in use.
As mentioned briefly previously, a considerable effort has 
been made by toxicologists to advance a new approach called 
the Adverse Outcome Pathway framework. This is an extension 
of the Mode of Action framework and is primarily being devel-
oped as an alternative solution to in-vivo toxicity testing. The 
framework is based on the idea that any adverse human health 
effect caused by exposure to an exogenous substance can be 
described by a series of causally linked biochemical or biologi-
cal key events with measurable parameters (28,490). Although 
the Adverse Outcome Pathway framework anticipates the pos-
sibility that multiple pathways may need to be defined (i.e. dif-
ferent pathways that can produce the same adverse human 
health effect), the concept is currently aligned with the mode 
of action approach and focuses mainly on individual chemi-
cal effects that follow a well-described pathway to produce an 
adverse health outcome. So as it is currently conceived, it has 
some of the same limitations that apply to the mode of action 
framework.
Nonetheless, this focus at a mechanistic level is progressive 
in nature and some researchers in this area are starting to call 
for the adoption of practices within the framework that can 
account for epigenetic effects, transgenerational effects and 
chronic toxicity (detrimental effects arising in individual or at 
the population level following long-term continuous or fluctu-
ating exposure to chemicals at sublethal concentrations—i.e. 
concentrations not high enough to cause mortality or directly 
observable impairment following acute, short-term exposure, 
but able to induce specific effects potentially leading to adverse 
outcomes occurring at a later point in time) (28).
So this framework may be suitable for research that is 
focused on mixtures of chemicals and the pathways involved 
in carcinogenesis, so long as the adherents to this approach 
are open to the possibility that all relevant pathways need not 
have adverse health outcomes as endpoints, and that synergies 
between pathways may need to be anticipated. In other words, 
a series of seemingly benign actions on different pathways may 
be needed to conspire to produce the adverse health outcome 
that is of interest. This is the case in cancer. There are so many 
layers of redundancy and safeguards in place that individual 
disruptions of certain pathways may never cause disease on 
their own. Yet, when a number of these pathways are enabled, 
they can produce a discernable adverse health outcome (i.e. 
cancer). If this approach is robust enough to anticipate this type 
of complexity, it may be a model that will allow us to move past 
the limitations imposed by the mode of action model.
Many regulatory agencies that conduct chemical risk assess-
ments also have a mandate to ensure that adequate safety 
margins are in place to protect sensitive subpopulations. So 
they will need to place an increasing emphasis on the inter-
play between environmental factors and genetic factors and 
also consider in-utero exposures and the potential for transgen-
erational effects. Some progress has been made in tackling the 
gene-environment interaction problem using pathway analysis 
to demonstrate the role of genetic variants in exposure-related 
cancer susceptibility (c.f. Malhotra et  al. (498)), but very little 
research has been done on in-utero exposures to mixtures of 
chemicals that act on cancer-related mechanisms. An approach 
that focuses on defining mixtures of constituents that act dis-
ruptively on key mechanisms that are related to individual hall-
marks may serve as a useful starting point to find evidence of 
relevant transgenerational effects (c.f. Singh et  al. (499)). This 
is definitely an area where additional research and regulatory 
input is needed.
Research needs: cancer versus carcinogenesis
One of the main challenges in this project has been the need 
to better understand carcinogenesis as a process characterized 
by a long latency—and the corollary possibility of both direct 
and indirect effects—rather than cancer as a disease endpoint 
that must occur rapidly and in the majority of exposed persons 
to be relevant. This was also accompanied the recognition that 
the Hallmarks of Cancer are frequently neither fixed nor spe-
cific for cancer (349–351). Numerous experimental models have 
been used in cancer research over the years, and Vineis et  al. 
(493) summarized them into at least five separate classes of 
models—see below:
(a) Mutational models
(b) Genome instability
(c)  Models based on non-genotoxic mechanisms, clonal 
expansion and epigenetics
(d) ‘Darwinian’ or ‘somatic cellular selection’, and
(e) ‘Tissue organization’.
All of these models have had significant support in the scientific 
literature (based upon empirical evidence) and there is consid-
erable overlap between them. But our collective understanding 
of carcinogenesis is still largely constrained by a historically 
monolithic toxicology-based approach that has been focused on 
the effects of mutagens and the disease itself. So although the 
Hallmarks of Cancer framework helps us to better conceptualize 
the many acquired capabilities of the disease, it leaves much to 
the imagination when it comes to advancing our understanding 
of carcinogenesis per se. This lacuna was recently highlighted by 
Brash et al. (494,495) in an article on what they called ‘the mys-
terious steps in carcinogenesis’.
Carcinogenesis appears to be an evolution of factors that 
ultimately conspire towards various acquired capabilities (i.e. 
those delineated within the Hallmarks of Cancer framework), 
but how much does the sequencing of these acquired capabili-
ties matter and in what order are these capabilities acquired? 
Figure  1 implies a rough sequencing of these capabilities, but 
do we know for certain that all hallmarks for established cancer 
are important for carcinogenesis as well (i.e. which hallmarks 
are necessary for all tumors, and of those, which are sufficient 
or perhaps distinct for certain cancers?). Other important ques-
tions to ask relate to whether or not the individual hallmarks 
are a cause or a consequence of cancer development? Do the 
individual hallmarks need to be expressed simultaneously or 
sequentially along the continuum of carcinogenesis (from expo-
sure to unambiguous cancer phenotype development)? More 
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importantly, how does our understanding of this framework 
inform our general approach to the study of carcinogenesis?
We have partial answers to some of these questions, but 
some of these questions remain unanswered, and given the 
prolonged latency of many cancers, these are important ques-
tions. Our lack of knowledge in this regard makes it difficult to 
draw immediate conclusions about the effects that exposures to 
mixtures of disruptive chemicals might cause and the synergies 
they might produce. Public health protection is challenged by 
the combinatorial complexity posed, not only by multiple expo-
sures to chemicals at environmentally relevant doses (either 
simultaneously or sequentially) but also through the different 
mechanisms played out in temporospatial manners (includ-
ing life stages of development, which are different from those 
applied in traditional toxicologic and carcinogenic screening).
We, therefore, need to consider an expanded research agenda 
to include the origins, determinants and temporospatial evolu-
tion of the various cancer hallmarks and their interrelatedness. 
The key questions of reversibility and of cause versus conse-
quence must also be rigorously addressed at every step from ini-
tiating carcinogenic exposure to established cancer, recognizing 
that not all hallmarks are either fixed or specific for any given 
cancer type.
Research needs: the Hallmarks of Cancer
Current approaches to the study of chemical exposures and car-
cinogenesis have not been designed to address effects at low 
concentrations or in complex mixtures. Procarcinogenic agents 
may be directly genotoxic, indirectly genotoxic or non-genotoxic. 
In principle, not every disruptive effect resulting in a change 
that mimics a cancer hallmark is necessarily carcinogenic. Such 
associations, when observed, still require rigorous validation to 
ensure that exposures are unequivocally linked to the develop-
ment of both cancer and accompanying phenotypic hallmarks. 
These complex interactional possibilities, coupled with the fact 
that low-dose combinatorial effects on cancer development 
and progression have not been rigorously or comprehensively 
addressed, speak to major gaps in our understanding of envi-
ronmental cancer risk and the specific role that mixtures of 
environmental chemical exposures might play in the incidence 
of cancer at the population level.
Unfortunately, the known effects for chemicals examined in 
isolation and at higher concentrations cannot be readily extrap-
olated to effects at lower concentrations. Interactions within 
complex mixtures will also occur against the backdrop of com-
plex interactions with other environmental, genetic and epige-
netic factors, so there is a need for expanded or complementary 
conceptual and experimental frameworks to better understand 
the determinants and specific functional contributions of envi-
ronmental exposures in cancer.
A considerable amount of energy is now being placed on the 
development of research and technologies that can support the 
‘exposome’ (496), an emerging concept aimed at representing 
the totality of chemical exposures received by a person during 
a lifetime. This approach encompasses all sources of toxicants 
and is intended to help researchers discern some of the contrib-
uting factors that are driving chronic diseases such as cancer. 
Related projects are expected to involve extensive biomoni-
toring (e.g. blood and urine sampling) and other techniques to 
assess biomarkers that might be relevant, and this information 
should be extremely helpful. Longitudinal studies should also 
be carried out in animal models to assess the tissue distribution 
of mixtures of chemical metabolites. To truly make good use 
of this information, we are going to need a better mechanistic 
understanding of the process of carcinogenesis itself and better 
early markers of cancer development.
It therefore makes sense to pursue empirical research based 
on our current understandings of the disease to test the effects 
of real-world environmental mixtures at relevant dose levels. 
Basic studies should be designed to test joint toxic action (of 
carefully designed combinations of chemicals) to assess both 
dose additivity (via common mode of action) and response addi-
tivity (via disparate modes of action). Research designs should 
anticipate the many layers of inherent defense and incorporate 
chemical constituents specifically intended to demonstrate pre-
dictable synergies and mechanistic relevance. It would also be 
useful to know whether or not the chemical induction of certain 
numbers/combinations of hallmarks is sufficient to consistently 
produce in-vivo carcinogenesis.
Mixtures research that focuses on the carcinogenic synergies 
of non-carcinogenic constituents would be particularly useful. 
In addition, compounds or classes of chemicals already consid-
ered to be (complete) carcinogens in the classical sense may also 
contribute to carcinogenesis in complex mixtures at concentra-
tions not traditionally deemed carcinogenic. For this reason 
and for completeness, ‘classic’ carcinogens with an established 
environmental presence at levels that are presumed to be incon-
sequential may still have pathogenic relevance and should be 
routinely included in the analysis.
Target sites that are being manipulated and disruptive chem-
icals that are being selected to produce carcinogenic effects 
should be scrutinized for confounding effects. Table 4 contains 
aggregated evidence of cross-hallmark effects for selected path-
ways/mechanisms, and although some target sites for disrup-
tion may be compelling starting points for researchers focused 
on a given phenotype (e.g. genetic instability), cross-hallmark 
relationships should be explored. So, for example, telomere loss 
is seen as a disruptive (procarcinogenic) effect from the per-
spective of the the genetic instability team (i.e. the group in this 
project who selected this target) and it has also been shown to 
exert procarcinogenic effects in four other hallmark areas. But 
evidence also exists that suggests that telomere loss can have 
anticarcinogenic effects in four other hallmark areas. The exact 
circumstances of the various studies that support these cross-
hallmark relationships would need to be reviewed to better 
understand the implications/relevance of these reported effects. 
But checking planned disruptions of each target across all of 
the other hallmark areas is a way to ensure that confounding 
(i.e. anticarcinogenic) effects are not inadvertantly introduced 
into experiments that are aimed at producing carcinogenesis, 
or phenotypes that can support/contribute to carcinogenesis. 
Similarly, Table  5 contains aggregated evidence of cross-hall-
mark effects for the chemical disruptors in this review, so this 
table can be used for the same purpose.
It may also be productive to identify ‘reference compounds’ 
(ideal and prototypical disruptors) for each hallmark path-
way as a guide to predict different combinations of chemicals 
that might act in a procarcinogenic manner on any one of 
the hallmarks. This may involve different systems and organs 
that have relevance to cancer and this sort of research could 
also be combined with similar sorts of research on other refer-
ence compounds or mixtures that are shown to enable other 
hallmarks. In doing so, researchers should evaluate epigenetic 
changes in multiple samples/organs/tissues from exposed ani-
mals/other experimental models using gene array technology, 
‘omics’ approaches, real-time imaging of tumors in 3D both in-
vitro (primary cells) and in-vivo models combined with molecu-
lar biomarkers of disease progression, and cellular immune 
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parameters. The combination of use of computational chemical 
genomics virtual screening (497), system biology/pharmacology 
and high-quality imaging techniques should help us find quan-
titative-structure-activity-relationship correlations between the 
chemical structure of dissimilar disruptors and experimental 
data on biological activity, physiological changes, in-vivo toxicity 
and 3D cellular protein dynamics.
It is also conceivable that the combined effects of hundreds of 
chemicals in the environment may be involved in the process of 
enabling carcinogenesis at the population level, so basic empiri-
cal research that can demonstrate carcinogenic effects with min-
imalistic combinations may initially be needed to reveal the more 
granular aspects of carcinogenesis. For example, initial research 
might test our assumptions of the step-wise progression of car-
cinogenesis using targeted mixtures of chemicals that exert LDE 
to test combinations of 2, 3, 4 chemicals etc. against specific 
hallmarks and then adding additional targets to move through 
the various steps that are believed to be needed to fully enable 
the process. Experiments of this nature may reveal increases 
as well as decreases in cancer risk when different mechanisms 
are disrupted and corresponding hallmark phenotypes are ena-
bled (depending on the timing of various disruptive exposures). 
Batteries of tests may ultimately be needed to evaluate whole 
mixtures and key components individually and in various com-
binations. HTS approaches will be particularly helpful here, and 
a tiered approach may make sense to look for disruptive combi-
nations, which can then be applied in vivo. Exposure sequenc-
ing and dosage may also be important and should be evaluated 
based on our current understandings of the biology of cancer.
In terms of setting research priorities, tissue fate is also a 
matter for consideration. It has been known for many years that 
certain chemicals have affinities for certain tissues, and radi-
otracer labeling studies that have been conducted on chemicals 
for regulatory purposes illustrate how certain chemicals tend 
to accumulate in certain tissues. Additionally, it is well known 
that some tissue types give rise to human cancers millions of 
times more often than other tissue types (498). So, researchers 
may want to focus their work on mixtures of disruptive chemi-
cals that prove to be complementary at a mechanistic level and 
individually known to accumulate in the same types of tissues, 
while at the same time choosing tissue types that are known to 
produce cancers more rapidly.
The work that has been done by the WHO IPCS on mode of 
action has been very useful. Understanding when chemicals 
operate through the same mode of action is definitely good 
information for analytical purposes, but given that we now rec-
ognize that non-carcinogens acting at very low-dose levels on 
different targets and mechanisms can still activate carcinogen-
esis-related pathways, the combined (carcinogenic) potential of 
the many commonly encountered chemicals within the envi-
ronment still needs to be evaluated.
Increasingly, our information is improving and there are 
several tools that researchers can use to improve their research 
designs. For example, ToxCast™ is an approach launched by 
the EPA in 2007 to develop ways to predict potential toxicity of 
chemicals and to develop a cost-effective approach for prior-
itizing the thousands of chemicals that need toxicity testing. 
The ToxCast™ database was used in this project by a number 
of the teams and an incredible amount of data are available on 
in-vitro tests (produced using HTS) for a wide range of chemi-
cals. For example, there are many results that are direct meas-
ures of actions related to important mechanisms found within 
the Hallmarks of Cancer framework, which would be useful for 
research focused along these lines.
Although the hallmark phenotypes in this project repre-
sent areas of cancer research for which there is considerable 
agreement, one critique of this framework is that it ignores the 
‘missing hallmark’ of dedifferentiation (351). As well, the com-
plexity encompassed by each of these areas of research is hum-
bling. Moreover, cancer is not a singular or fixed entity, which 
frequently limits the ability to generalize about cancer biology 
(349–351). In a recent reflection on his career, Weinberg et  al. 
(499) noted not only widespread acceptance of the ‘Hallmarks of 
Cancer’ heuristic but also that this attempt to simplify the dis-
ease is rapidly being eclipsed by calls from the next generation 
of researchers who are now focused on assembling and analyz-
ing enormous data sets to gain an increasingly sophisticated 
understanding of cancer (e.g. genomes, transcriptomes, pro-
teomes—including isoforms, post-translational modifications 
and proteoforms, epigenomes, kinomes, methylomes, glycomes 
and matrisomes—each one of which encompasses staggering 
amounts of accumulated information) (499).
Many researchers have called for an analytical use of sys-
tems biology to transcend the study of individual genes/proteins 
and to integrate this complexity into higher order phenotypes 
(500,501). Systems biology enables researchers to identify prop-
erties that emerge from complex chemical–biological systems 
by probing how changes in one part affect the others and the 
behavior of the whole system. The combined effects of tens, 
if not hundreds, of simultaneous exposures may need to be 
accounted for. The fundamental challenge is that such models 
require parameters that are driven by data, but there are very 
few good examples of research on mixtures at environmentally 
relevant dose levels (502) (c.f. Porter et al. (510)), and there are 
fewer still that are focused on cancer.
Nonetheless, in the near term, this basic framework should 
serve as a useful starting point for foundational research and 
government funding agencies should consider new ways to 
support large-scale, team-based holistic approaches to this 
problem.
Regulatory priorities (in the face of combinatorial 
complexity)
It will take time before we fully understand the carcinogenic 
potential of low-dose exposures to chemical mixtures in the 
environment. Nonetheless, we cannot afford to lose sight of 
the fact that the incidence of cancer remains unacceptably 
high, and that the unavoidable (i.e. not lifestyle related) causa-
tive factors that are, in part, underpinning this trend are still 
not fully understood (9–11,504,505). Populations worldwide are 
continually exposed to a wide range of chemicals, so keeping 
the precautionary principle in mind (506), there is a need to take 
the risks related to the cumulative effects of these chemicals 
seriously (422). Of primary concern is the fact that WHO IPCS 
mode of action framework (477) and the OECD guidelines for 
risk assessment (480) are restrictive to the point that regulators 
could be underestimating the risks posed by exposures to low 
doses of mixtures of chemicals.
National regulatory agencies and cancer research founda-
tions must proactively pursue empirical research programs to 
assess any basic relationships that can be discerned between 
exposures to mixtures of commonly encountered chemicals and 
carcinogenicity. For example, systematic exploratory research in 
appropriate rodent models exposed to ‘whole-mixtures’ that 
consist of multiple chemical constituents at environmentally 
relevant dose levels could demonstrate the carcinogenic poten-
tial of complex mixtures that are relevant to the population. 
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There is also a compelling need for complementary basic 
research to address specific causal relationships between envi-
ronmental exposures and the associated development of cancer 
and its characteristic hallmarks.
Hypothetically speaking, such a ‘whole mixture’ should be 
composed of non-carcinogens and potential carcinogens given 
that individual chemicals that are not carcinogenic could act on a 
range of different systems, tissues and/or cells and act synergisti-
cally with other chemicals to instigate carcinogenesis. The goal of 
such investigations would not be to single out any given chemical 
as a carcinogen, but rather to determine whether or not unantici-
pated (procarcinogenic) synergies of many commonly encoun-
tered chemicals when combined are endangering public health.
In line with the 3Rs (Reduction, Replacement and Refinement) 
guiding principles for more ethical use of animals in scientific 
experiments, there has been a significant push for research-
ers and regulatory agencies to move away from in-vivo testing 
(e.g. European Union REACH legislation and in the USA, the NRC 
Toxicology for the 21st Century vision (507)) to take advantage 
of HTS and other new technologies. The EPA’s effort to search 
for environmental chemicals that are most active in relevant 
assays across the various cancer hallmarks, and then to com-
pare those results with in-vivo rodent carcinogenicity data for 
the same chemicals, was a definite step in this direction (29). 
However, HTS models of carcinogenicity will require validation, 
and significant hurdles remain before this sort of testing will 
be ready to replace in-vivo research (508). Therefore, in the near 
term, in-vivo testing still remains an important avenue for devel-
oping data sets to address cancer risks of complex mixtures. 
Summary/Conclusions
For several decades, there has been a concerted effort to iden-
tify individual chemicals and other agents that are carcinogenic. 
At the same time, however, little has been done to determine 
whether or not chronic lifetime exposures to mixtures of non-
carcinogenic chemicals in the environment (at low-dose lev-
els) have carcinogenic potential. Many chemicals are known to 
accumulate in bodily tissues over time, but little is known about 
their combined effects at a mechanistic level and their impact 
on cancer-related mechanisms and carcinogenesis. In this pro-
ject, teams of cancer biologists worked with researchers in the 
field of environmental health for the very first time to explore 
this possibility.
Teams that reviewed these cancer-related phenotypes (i.e. 
genetic instability, tumor-promoting inflammation, sustained 
proliferative signaling, insensitivity to antigrowth signals, resist-
ance to cell death, angiogenesis, tissue invasion and metastasis, 
the tumor microenvironment and avoiding immune destruc-
tion) readily identified individual (non-carcinogenic) chemicals 
that are ubiquitous in the environment that have some poten-
tial to act on key/priority functional targets in each of these 
domains. In contrast, the teams focused on replicative immortality 
and dysregulated metabolism found examples of chemicals to con-
sider but noted a significant lack of useful toxicological research 
in these areas.
In total, 85 examples of environmental chemicals were 
reviewed as prototypical disruptors (for specific actions on key 
pathways/mechanisms that are important for carcinogenesis) 
and 59% of them (i.e. 50/85) were found to exert LDE (at levels that 
are deemed relevant given the background levels of exposure that 
exist in the environment) with 15 of the 50 demonstrating their 
LDE in a non-linear dose-response pattern. Only 15% of the chem-
icals reviewed (i.e. 13/85) were found to have a dose-response 
threshold and the remaining 26% (i.e. 22/85) were categorized as 
‘unknown’ due to a lack of dose-response information.
Cross-hallmark effects for all target sites for disruption and 
for all chemicals were found, but the evidence supporting these 
results varied considerably in strength and in context.
A number of the teams also cited relevant in-utero expo-
sure studies in their reviews and presented data on transgen-
erational effects related to different aspects of the disease (e.g. 
inflammation, immune evasion and so on). These examples 
raise intriguing possibilities about vulnerabilities at the popu-
lation level, and the contributions that in-utero and early life 
exposures to mixtures of those chemicals might make towards 
cancer susceptibility.
Therefore, current regulations in many countries (that con-
sider only the cumulative effects of exposures to individual 
carcinogens that act via a common sequence of key events and 
processes on a common target/tissue to produce cancer) should 
be revisited. Our current understanding of the biology of can-
cer suggests that the cumulative effects of (non-carcinogenic) 
chemicals acting on different pathways that are relevant to 
cancer, and on a variety of cancer-relevant systems, organs, tis-
sues and cells could conspire to produce carcinogenic synergies 
that will be overlooked using current risk assessment methods. 
Cumulative risk assessment methods that are based on ‘com-
mon mechanisms of toxicity’ or common ‘modes of action’ may 
therefore be underestimating cancer-related risks. In-utero and 
early life exposures, transgenerational effects and the interplay 
between the low-dose mechanistic effects of chemical mixtures 
in the environment and the vulnerabilities of subpopulations 
who are predisposed to cancer (i.e. via genetics or other influ-
ences) must also be considered. Current policies and practices 
do not adequately address these issues and should therefore be 
revisited if regulatory agencies hope to better understand and 
assess these risks.
Finally, given the long latency period in most cancers, early 
detection to cancer is key so an improved understanding of the 
biology within originating tissues (during the latency period) 
would be very helpful. If we can use the heuristic presented in 
this review to better assess the combined effects of common 
exposures to chemical mixtures in the environment, it will help 
us improve our understanding of carcinogenesis and identify 
exogenous triggers and enabling factors (in utero and during 
this important latency period), all of which will be key for the 
development of effective strategies for prevention and early 
detection.
Contributions
The first draft of this manuscript (prepared by W.H.G.) was distrib-
uted to all of the contributors within the task force for feedback 
and additional inputs. The many responses that followed were 
managed by W.H.G. (with the assistance of L.Lo., M.G. and D.O.C.). 
Then, multiple rounds of inputs were solicited from the entire task 
force with several subsequent rounds of revisions and refinements 
prior to submission. In addition to the contributions mentioned 
previously, The Halifax Project also benefited from the involve-
ment of D.J.C. (who provided details, at the workshop in Halifax, 
Nova Scotia, Canada, of National Institute of Environmental 
Health Sciences priorities and the agency’s interest in unravel-
ling the health effects of environmental mixtures) and from Glenn 
Rice (who gave a Halifax workshop presentation on the chemical 
mixtures as a consideration in cancer risk assessment). Both of 
these presenters were included in the iterative rounds of manu-
script revisions mentioned previously, and both offered inputs that 
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resulted in refinements to the manuscript. Finally, the journal’s 
peer-review process was important, and resulted in the collection 
of additional evidence from the teams that related to thresholds, 
LDE and of non-monotonic dose-response relationships. The 
reviewer’s critical analysis on these topics resulted in a substantial 
improvement to the data presented in this capstone document, 
which ultimately served to highlight the extent to which low-dose 
exposures to individual chemical constituents (within mixtures of 
environmental chemicals) might have relevance for the process of 
carcinogenesis. Dose-response characterization data and inputs 
were then submitted by all teams and subsequently reviewed and 
compiled by N.K., A.Co. and R.M.
The Halifax Project Task Force that worked on this manuscript 
involved nearly 200 people, many of whom contributed to, and 
signed on to this capstone article. The design of the Halifax Project 
was conceived by L.Lo. with scientific advice from M.G. Funding 
provided by the National Institute for Environmental Health 
Sciences was arranged by D.O.C., and this manuscript was first 
drafted by W.H.G. Starting with the Hallmarks of Cancer frame-
work (Hanahan et al. (21)), 11 teams of international cancer biolo-
gists and toxicologists were established to review the literature 
on key cancer-related mechanisms/pathways in their respective 
domains and to also look at the disruptive potential of low-dose 
exposures to chemicals commonly encountered in the environ-
ment (i.e. as it relates to those same mechanisms/pathways). 
Each team had a leader and each team was responsible for con-
tributing a section of related content within the capstone manu-
script. The contributing authors from these teams are as follows: 
(1) Angiogenesis (Z.H., C-W.H., H-Y.H., L-T.L., M.X., N.K., S.A.B., 
T.M., V.D., W.K.R.); (2) Dysregulated metabolism (R.B.R., A.C.S., 
A.B., E.Ry., D.B., F.C., F.L.M., G.Wi., J.We., N.B.K., R.P.); (3) Evasion of 
antigrowth signaling (R.N., A.L., C.C.N., D.W.L., D.R., G.S.G., G.M.C., 
H.Kr., J.V., K.A.C-S., M.W., N.C., P.A.M., P.De., R.A-V., R.V., R.D.F., R.P-
C., R.C.C., S.N.B.), (4) Genetic instability (S.A.S.L., A.L.d.C.S., A.Az., 
A.K.C., A.R.C., A-K.O., E.Ro., F.D., F.J.V.S., G.K., G.B., L.Go., L.Le., L.Z., 
M.Val., M.K-V., N.v L., P.O-W., S.Pav., T.C.); (5) Immune system eva-
sion (H.K.L., E.C., J.K., M.A.W., M.H.M., T.O., W.K.D.), (6) Replicative 
immortality (A.Ca., C.B-A., H.Y., H.Ko., J.P.W., J.F.M-L., M.L., S.S.W.); 
(7) Resistance to cell death (H.H.P., A.M.A., B.J.B., C.Y., E.R., K.B.N., 
L.S.D’A., L.Li., M.F.R., M.J.G., P.M.G., P.S.L., Q.(S.) C., R.K.S., R.D., S.Ro., 
S.L., T-J.L., Y.R.); (8) Sustained proliferative signaling (W.E., A.W., 
G.Wa., H.S., J.E.K., J.R., K.M., L.Gu., M.V.K., P.V., P.Da., R.M., S.Er., 
T.S., T.H.); (9) Tissue invasion and metastasis (J.O., B.P.Z., C.D., G.N., 
G.T.W., I.K., I.R.M., L.J.M., N.A., O.O., P.N-M., S.El., S.Pap., V.O-M., Y.L., 
Z.C.); (10) Tumor microenvironment (D.W.F., C.S.C., D.C.K., E.L., 
F.M., J.Ro., J.C., J.R.W., L.S., L.V., M.C., P.K.K., P.H., S.Ry., S.C.C., V.M-
S.) and (11) Tumor-promoting inflammation (P.T., C.B., E-Y. M., J.S., 
L.J., M.K., S.H., T.G., V.S.).** Additionally, a special cross-functional 
team was established to investigate whether or not the chemi-
cals that were identified by the teams as having disruptive poten-
tial for key mechanisms/pathways in a particular domain might 
also have been shown in other research to exert relevant effects 
on mechanisms/pathways in other domains. The results of the 
efforts from this team have been compiled and summarized in 
this article and can be found within Table 4. This team was com-
prised as follows: W.H.B., A.Am., I.S., A.Co., C.M., D.B., E.Ry., F.A-
M., H.A.H., H.K.S., J.Ra., J.Wo., K.R.P., L.M., M.Vac., N.S., R.A-T., R.R., 
R.A.H. and S.F.** **Note that team leaders are denoted by the first 
set of initials in each team list.
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